



PCT/GB 00 / 02569



INVESTOR IN PEOPLE

18 AUG 2000

PRIORITY

DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


GB00/02569 10/019800

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

R. Mahoney

Dated

18th July 2000



Handwritten signature or scribble at the bottom left of the page.

The Patent Office

Patents Act 1977

16)

1/77

150ED99 E4993 7-1 00103
P0177700 4.004992547.9

Request for grant of a patent

14 DEC 1999

The Patent Office

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

Cardiff Road

Newport

Gwent NP9 1RH

14 DEC 1999

1. Your Reference **MLR/PG3884**

2. Patent application number
(The Patent office will fill in this part)

9929547.9

3. Full name, address and postcode of the or of each applicant (underline all surnames)

**GLAXO GROUP LIMITED
GLAXO WELLCOME HOUSE
BERKELEY AVENUE
GREENFORD
MIDDLESEX
UB6 ONN
GB**

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its corporation

GB

4. Title of the invention **DNA CONSTRUCTS**

5. Name of your agent (if you know one) **MARION L REES (SEE CONTINUATION SHEET)**

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

**GLAXO WELLCOME PLC
GLAXO WELLCOME HOUSE, BERKELEY AVENUE
GREENFORD, MIDDLESEX
UB6 ONN, GB**

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of Filing (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.

YES

See note (i1)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	1
Description	35
Claim(s)	4
Abstract	1
Drawing(s)	17

10. If you are also filing any of the following,
state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patent Form 9/77*)

Request for substantive examination (*Patent Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application

Signature *Marion L Rees* 14 December 1999
AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of person to contact in the United Kingdom
CATE WEST
0181-966 8685

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) Notes

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form
If you have answered "Yes" Patents Form 7/77 will need to be filed.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.

Additional Agents


(See Page 1 No. 5)

NAME(S)

Alan HESKETH
 Michael ATKINSON
 Karen CRAWLEY
 Peter I. DOLTON
 Hugh B. DAWSON
 Wendy Anne FILLER
 Christiane Elizabeth FISHER
 Ruth Elizabeth HACKETT
 Audrey HAMMETT
 Siân Catherine HOCKLEY
 Graham M.H. LANE
 Stephanie Anne LEAROYD
 Helen Kaye QUILLIN
 Michael A REED
 Marion REES
 Michael John STOTT
 Andrew J. TEUTEN
 Rachel M. THORNLEY
 Janis Florence VOLCKMAN

ADDRESS

Glaxo Wellcome plc
 Glaxo Wellcome-House
 Berkeley Avenue
 Greenford
 Middlesex
 UB6 ONN
 Great Britain



1937-1938 1939-1940 1941-1942 1943-1944 1945-1946 1947-1948 1949-1950 1951-1952 1953-1954 1955-1956 1957-1958 1959-1960 1961-1962 1963-1964 1965-1966 1967-1968 1969-1970 1971-1972 1973-1974 1975-1976 1977-1978 1979-1980 1981-1982 1983-1984 1985-1986 1987-1988 1989-1990 1991-1992 1993-1994 1995-1996 1997-1998 1999-2000 2001-2002 2003-2004 2005-2006 2007-2008 2009-2010 2011-2012 2013-2014 2015-2016 2017-2018 2019-2020 2021-2022 2023-2024 2025-2026 2027-2028 2029-2030 2031-2032 2033-2034 2035-2036 2037-2038 2039-2040 2041-2042 2043-2044 2045-2046 2047-2048 2049-2050 2051-2052 2053-2054 2055-2056 2057-2058 2059-2060 2061-2062 2063-2064 2065-2066 2067-2068 2069-2070 2071-2072 2073-2074 2075-2076 2077-2078 2079-2080 2081-2082 2083-2084 2085-2086 2087-2088 2089-2090 2091-2092 2093-2094 2095-2096 2097-2098 2099-2100 2101-2102 2103-2104 2105-2106 2107-2108 2109-2110 2111-2112 2113-2114 2115-2116 2117-2118 2119-2120 2121-2122 2123-2124 2125-2126 2127-2128 2129-2130 2131-2132 2133-2134 2135-2136 2137-2138 2139-2140 2141-2142 2143-2144 2145-2146 2147-2148 2149-2150 2151-2152 2153-2154 2155-2156 2157-2158 2159-2160 2161-2162 2163-2164 2165-2166 2167-2168 2169-2170 2171-2172 2173-2174 2175-2176 2177-2178 2179-2180 2181-2182 2183-2184 2185-2186 2187-2188 2189-2190 2191-2192 2193-2194 2195-2196 2197-2198 2199-2200 2201-2202 2203-2204 2205-2206 2207-2208 2209-2210 2211-2212 2213-2214 2215-2216 2217-2218 2219-2220 2221-2222 2223-2224 2225-2226 2227-2228 2229-2230 2231-2232 2233-2234 2235-2236 2237-2238 2239-2240 2241-2242 2243-2244 2245-2246 2247-2248 2249-2250 2251-2252 2253-2254 2255-2256 2257-2258 2259-2260 2261-2262 2263-2264 2265-2266 2267-2268 2269-2270 2271-2272 2273-2274 2275-2276 2277-2278 2279-2280 2281-2282 2283-2284 2285-2286 2287-2288 2289-2290 2291-2292 2293-2294 2295-2296 2297-2298 2299-2300 2301-2302 2303-2304 2305-2306 2307-2308 2309-2310 2311-2312 2313-2314 2315-2316 2317-2318 2319-2320 2321-2322 2323-2324 2325-2326 2327-2328 2329-2330 2331-2332 2333-2334 2335-2336 2337-2338 2339-2340 2341-2342 2343-2344 2345-2346 2347-2348 2349-2350 2351-2352 2353-2354 2355-2356 2357-2358 2359-2360 2361-2362 2363-2364 2365-2366 2367-2368 2369-2370 2371-2372 2373-2374 2375-2376 2377-2378 2379-2380 2381-2382 2383-2384 2385-2386 2387-2388 2389-2390 2391-2392 2393-2394 2395-2396 2397-2398 2399-2400 2401-2402 2403-2404 2405-2406 2407-2408 2409-2410 2411-2412 2413-2414 2415-2416 2417-2418 2419-2420 2421-2422 2423-2424 2425-2426 2427-2428 2429-2430 2431-2432 2433-2434 2435-2436 2437-2438 2439-2440 2441-2442 2443-2444 2445-2446 2447-2448 2449-2450 2451-2452 2453-2454 2455-2456 2457-2458 2459-2460 2461-2462 2463-2464 2465-2466 2467-2468 2469-2470 2471-2472 2473-2474 2475-2476 2477-2478 2479-2480 2481-2482 2483-2484 2485-2486 2487-2488 2489-2490 2491-2492 2493-2494 2495-2496 2497-2498 2499-2500 2501-2502 2503-2504 2505-2506 2507-2508 2509-2510 2511-2512 2513-2514 2515-2516 2517-2518 2519-2520 2521-2522 2523-2524 2525-2526 2527-2528 2529-2530 2531-2532 2533-2534 2535-2536 2537-2538 2539-2540 2541-2542 2543-2544 2545-2546 2547-2548 2549-2550 2551-2552 2553-2554 2555-2556 2557-2558 2559-2560 2561-2562 2563-2564 2565-2566 2567-2568 2569-2570 2571-2572 2573-2574 2575-2576 2577-2578 2579-2580 2581-2582 2583-2584 2585-2586 2587-2588 2589-2590 2591-2592 2593-2594 2595-2596 2597-2598 2599-2600 2601-2602 2603-2604 2605-2606 2607-2608 2609-2610 2611-2612 2613-2614 2615-2616 2617-2618 2619-2620 2621-2622 2623-2624 2625-2626 2627-2628 2629-2630 2631-2632 2633-2634 2635-2636 2637-2638 2639-2640 2641-2642 2643-2644 2645-2646 2647-2648 2649-2650 2651-2652 2653-2654 2655-2656 2657-2658 2659-2660 2661-2662 2663-2664 2665-2666 2667-2668 2669-2670 2671-2672 2673-2674 2675-2676 2677-2678 2679-2680 2681-2682 2683-2684 2685-2686 2687-2688 2689-2690 2691-2692 2693-2694 2695-2696 2697-2698 2699-2700 2701-2702 2703-2704 2705-2706 2707-2708 2709-2710 2711-2712 2713-2714 2715-2716 2717-2718 2719-2720 2721-2722 2723-2724 2725-2726 2727-2728 2729-2730 2731-2732 2733-2734 2735-2736 2737-2738 2739-2740 2741-2742 2743-2744 2745-2746 2747-2748 2749-2750 2751-2752 2753-2754 2755-2756 2757-2758 2759-2760 2761-2762 2763-2764 2765-2766 2767-2768 2769-2770 2771-2772 2773-2774 2775-2776 2777-2778 2779-2780 2781-2782 2783-2784 2785-2786 2787-2788 2789-2790 2791-2792 2793-2794 2795-2796 2797-2798 2799-2800 2801-2802 2803-2804 2805-2806 2807-2808 2809-2810 2811-2812 2813-2814 2815-2816 2817-2818 2819-2820 2821-2822 2823-2824 2825-2826 2827-2828 2829-2830 2831-2832 2833-2834 2835-2836 2837-2838 2839-2840 2841-2842 2843-2844 2845-2846 2847-2848 2849-2850 2851-2852 2853-2854 2855-2856 2857-2858 2859-2860 2861-2862 2863-2864 2865-2866 2867-2868 2869-2870 2871-2872 2873-2874 2875-2876 2877-2878 2879-2880 2881-2882 2883-2884 2885-2886 2887-2888 2889-2890 2891-2892 2893-2894 2895-2896 2897-2898 2899-2900 2901-2902 2903-2904 2905-2906 2907-2908 2909-2910 2911-2912 2913-2914 2915-2916 2917-2918 2919-2920 2921-2922 2923-2924 2925-2926 2927-2928 2929-2930 2931-2932 2933-2934 2935-2936 2937-2938 2939-2940 2941-2942 2943-2944 2945-2946 2947-2948 2949-2950 2951-2952 2953-2954 2955-2956 2957-2958 2959-2960 2961-2962 2963-2964 2965-2966 2967-2968 2969-2970 2971-2972 2973-2974 2975-2976 2977-2978 2979-2980 2981-2982 2983-2984 2985-2986 2987-2988 2989-2990 2991-2992 2993-2994 2995-2996 2997-2998 2999-3000 3001-3002 3003-3004 3005-3006 3007-3008 3009-3010 3011-3012 3013-3014 3015-3016 3017-3018 3019-3020 3021-3022 3023-3024 3025-3026 3027-3028 3029-3030 3031-3032 3033-3034 3035-3036 3037-3038 3039-3040 3041-3042 3043-3044 3045-3046 3047-3048 3049-3050 3051-3052 3053-3054 3055-3056 3057-3058 3059-3060 3061-3062 3063-3064 3065-3066 3067-3068 3069-3070 3071-3072 3073-3074 3075-3076 3077-3078 3079-3080 3081-3082 3083-3084 3085-3086 3087-3088 3089-3090 3091-3092 3093-3094 3095-3096 3097-3098 3099-3100 3101-3102 3103-3104 3105-3106 3107-3108 3109-3110 3111-3112 3113-3114 3115-3116 3117-3118 3119-3120 3121-3122 3123-3124 3125-3126 3127-3128 3129-3130 3131-3132 3133-3134 3135-3136 3137-3138 3139-3140 3141-3142 3143-3144 3145-3146 3147-3148 3149-3150 3151-3152 3153-3154 3155-3156 3157-3158 3159-3160 3161-3162 3163-3164 3165-3166 3167-3168 3169-3170 3171-3172 3173-3174 3175-3176 3177-3178 3179-3180 3181-3182 3183-3184 3185-3186 3187-3188 3189-3190 3191-3192 3193-3194 3195-3196 3197-3198 3199-3200 3201-3202 3203-3204 3205-3206 3207-3208 3209-3210 3211-3212 3213-3214 3215-3216 3217-3218 3219-3220 3221-3222 3223-3224 3225-3226 3227-3228 3229-3230 3231-3232 3233-3234 3235-3236 3237-3238 3239-3240 3241-3242 3243-3244 3245-3246 3247-3248 3249-3250 3251-3252 3253-3254 3255-3256 3257-3258 3259-3260 3261-3262 3263-3264 3265-3266 3267-3268 3269-3270 3271-3272 3273-3274 3275-3276 3277-3278 3279-3280 3281-3282 3283-3284 3285-3286 3287-3288 3289-3290 3291-3292 3293-3294 3295-3296 3297-3298 3299-3300 3301-3302 3303-3304 3305-3306 3307-3308 3309-3310 3311-3312 3313-3314 3315-3316 3317-3318 3319-3320 3321-3322 3323-3324 3325-3326 3327-3328 3329-3330 3331-3332 3333-3334 3335-3336 3337-3338 3339-3340 3341-3342 3343-3344 3345-3346 3347-3348 3349-3350 3351-3352 3353-3354 3355-3356 3357-3358 3359-3360 3361-3362 3363-3364 3365-3366 3367-3368 3369-3370 3371-3372 3373-3374 3375-3376 3377-3378 3379-3380 3381-3382 3383-3384 3385-3386 3387-3388 3389-3390 3391-3392 3393-3394 3395-3396 3397-3398 3399-3400 3401-3402 3403-3404 3405-3406 3407-3408 3409-3410 3411-3412 3413-3414 3415-3416 3417-3418 3419-3420 3421-3422 3423-3424 3425-3426 3427-3428 3429-3430 3431-3432 3433-3434 3435-3436 3437-3438 3439-3440 3441-3442 3443-3444 3445-3446 3447-3448 3449-3450 3451-3452 3453-3454 3455-3456 3457-3458 3459-3460 3461-3462 3463-3464 3465-3466 3467-3468 3469-3470 3471-3472 3473-3474 3475-3476 3477-3478 3479-3480 3481-3482 3483-3484 3485-3486 3487-3488 3489-3490 3491-3492 3493-3494 3495-3496 3497-3498 3499-3500 3501-3502 3503-3504 3505-3506 3507-3508 3509-3510 3511-3512 3513-3514 3515-3516 3517-3518 3519-3520 3521-3522 3523-3524 3525-3526 3527-3528 3529-3530 3531-3532 3533-3534 3535-3536 3537-3538 3539-3540 3541-3542 3543-3544 3545-3546 3547-3548 3549-3550 3551-3552 3553-3554 3555-3556 3557-3558 3559-3560 3561-3562 3563-3564 3565-3566 3567-3568 3569-3570 3571-3572 3573-3574 3575-3576 3577-3578 3579-3580 3581-3582 3583-3584 3585-3586 3587-3588 3589-3590 3591-3592 3593-3594 3595-3596 3597-3598 3599-3600 3601-3602 3603-3604 3605-3606 3607-3608 3609-3610 3611-3612 3613-3614 3615-3616 3617-3618 3619-3620 3621-3622 3623-3624 3625-3626 3627-3628 3629-3630 3631-3632 3633-3634 3635-3636 3637-3638 3639-3640 3641-3642 3643-3644 3645-3646 3647-3648 3649-3650 3651-3652 3653-3654 3655-3656 3657-3658 3659-3660 3661-3662 3663-3664 3665-3666 3667-3668 3669-3670 3671-3672 3673-3674 3675-3676 3677-3678 3679-3680 3681-3682 3683-3684 3685-3686 3687-3688 3689-3690 3691-3692 3693-3694 3695-3696 3697-3698 3699-3700 3701-3702 3703-3704 3705-3706 3707-3708 3709-3710 3711-3712 3713-3714 3715-3716 3717-3718 3719-3720 3721-3722 3723-3724 3725-3726 3727-3728 3729-3730 3731-3732 3733-3734 3735-3736 3737-3738 3739-3740 3741-3742 3743-3744 3745-3746 3747-3748 3749-3750 3751-3752 3753-3754 3755-3756 3757-3758 3759-3760 3761-3762 3763-3764 3765-3766 3767-3768 3769-3770 3771-3772 3773-3774 3775-3776 3777-3778 3779-3780 3781-3782 3783-3784 3785-3786 3787-3788 3789-3790 3791-3792 3793-3794 3795-3796 3797-3798 3799-3800 3801-3802 3803-3804 3805-3806 3807-3808 3809-3810 3811-3812 3813-3814 3815-3816 3817-3818 3819-3820 3821-3822 3823-3824 3825-3826 3827-3828 3829-3830 3831-3832 3833-3834 3835-3836 3837-3838 3839-3840 3841-3842 3843-3844 3845-3846 3847-3848 3849-3850 3851-3852 3853-3854 3855-3856 3857-3858 3859-3860 3861-3862 3863-3864 3865-3866 3867-3868 3869-3870 3871-3872 3873-3874 3875-3876 3877-3878 3879-3880 3881-3882 3883-3884 3885-3886 3887-3888 3889-3890 3891-3892 3893-3894 3895-3896 3897-3898 3899-3900 3901-3902 3903-3904 3905-3906 3907-3908 3909-3910 3911-3912 3913-3914 3915-3916 3917-3918 3919-3920 3921-3922 3923-3924 3925-3926 3927-3928 3929-3930 3931-3932 3933-3934 3935-3936 3937-3938 3939-3940 3941-3942 3943-3944 3945-3946 3947-3948 3949-3950 3951-3952 3953-3954 3955-3956 3957-3958 3959-3960 3961-3962 3963-3964 3965-3966 3967-3968 3969-3970 3971-3972 3973-3974 3975-3976 3977-3978 3979-3980 3981-3982 3983-3984 3985-3986 3987-3988 3989-3990 3991-3992 3993-3994 3995-3996 3997-3998 3999-4000 4001-4002 4003-4004 4005-4006 4007-4008 4009-4010 4011-4012 4013-4014 4015-4016 4017-4018 4019-4020 4021-4022 4023-4024 4025-4026 4027-4028 4029-4030 4031-4032 4033-4034 4035-4036 4037-4038 4039-4040 4041-4042 4043-4044 4045-4046 4047-4048 4049-4050 4051-4052 4053-4054 4055-4056 4057-4058 4059-4060 4061-4062 4063-4064 4065-4066 4067-4068 4069-4070 4071-4072 4073-4074 4075-4076 4077-4078 4079-4080 4081-4082 4083-4084 4085-4086 4087-4088 4089-4090 4091-4092 4093-4094 4095-4096 4097-4098 4099-4100 4101-4102 4103-4104 4105-4106 4107-4108 4109-4110 4111-4112 4113-4114 4115-4116 4117-4118 4119-4120 4121-4122 4123-4124 4125-4126 4127-4128 4129-4130 4131-4132 4133-4134 4135-4136 4137-4138 4139-4140 4141-4142 4143-4144 4145-4146 4147-4148 4149-4150 4151-4152 4153-4154 4155-4156 4157-4158 4159-4160 4161-4162 4163-4164 4165-4166 4167-4168 4169-4170 4171-4172 4173-4174 4175-4176 4177-4178 4179-4180 4181-4182 4183-4184 4185-4186 4187-4188 4189-4190 4191-4192 4193-4194 4195-4196 4197-4198 4199-4200 4201-4202 4203-4204 4205-4206 4207-4208 4209-4210 4211-4212 4213-4214 4215-4216 4217-4218 4219-4220 4221-4222 4223-4224 4225-4226 4227-4228 4229-4230 4231-4232 4233-4234 4235-4236 4237-4238 4239-4240 4241-4242 4243-4244 4245-4246 4247-4248 4249-4250 4251-4252 4253-4254 4255-4256 4257-4258 4259-4260 4261-4262 4263-4264 4265-4266 4267-4268 4269-4270 4271-4272 4273-4274 4275-4276 4277-4278 4279-4280 4281-4282 4283-4284 4285-4286 4287-4288 4289-4290 4291-4292 4293-4294 4295-4296 4297-4298 4299-4300 4301-4302 4303-4304 4305-4306 4307-4308 4309-4310 4311-4312 4313-4314 4315-4316 4317-4318 4319-4320 4321-4322 4323-4324 4325-4326 4327-4328 4329-4330 4331-4332 4333-4334 4335-4336 4337-4338 4339-4340 4341-4342 4343-4344 4345-4346 4347-4348 4349-4350 4351-4352 4353-4354 4355-4356 4357-4358 4359-4360 4361-4362 4363-4364 4365-4366 4367-4368 4369-4370 4371-4372 4373-

DNA Constructs

The present invention concerns novel DNA constructs, host cells comprising (harbouring) said constructs, methods and processes for the production of a desired protein, particularly a therapeutically useful protein, DNA vaccines and other medicaments comprising said constructs and methods of gene therapy using said constructs.

Eukaryotic Initiation Factor 4A (eIF-4A) is a 43kD protein with RNA helicase activity that mediates binding of mRNA to the 40S subunit of the ribosome. In the mouse genome there are two functional eIF4A genes, eIF4A_I and eIF4A_{II} (1,2). The two eIF4A genes are differentially regulated in the mouse with eIF4A_I mRNA being expressed at higher levels than the eIF4A_{II} mRNA in dividing cells with the eIF4A_{II} mRNA being preferentially expressed in non dividing cells (3). In the human genome the homologous eIF-4A_I and eIF-4A_{II} genes have been mapped to chromosomes 17p13 and 18p11.2 respectively (4,5).

In common with many other 'housekeeping genes' the gene encoding eIF-4A_I must be expressed in every mammalian cell type at approximately similar levels.

Many housekeeping gene promoters do not contain TATA box sequences to direct transcription initiation but rather have GC rich promoters that contain binding sites for the transcription factor Sp1 and initiator elements (6). Many housekeeping gene promoters contain a higher than expected frequency of the dinucleotide CpG and these regions are not as extensively methylated as other CpG dinucleotides elsewhere in the genome (7). Such Methylation Free Islands (MFI) are often associated with transcriptional regulatory regions of genes and are thought to act by maintaining adjacent chromatin regions in an open configuration (8).

Cloning of the genes defective in human monogenic diseases such as the Cystic Fibrosis has raised the possibility of introducing a non mutated form of the Cystic Fibrosis Transmembrane Regulator (CFTR) gene into the appropriate cell types of affected individuals to restore normal function. In order for such somatic gene therapy protocols to be useful the therapeutic gene of interest must be stably expressed at a level similar to or higher than that of the mutated gene. Nearly

all somatic gene therapy vectors used to date have relied upon transcriptional regulatory regions derived from viruses such as the SV40 enhancer, retroviral Long Terminal Repeat sequences or the promoter/enhancer element of the human Cytomegalovirus immediate early gene. While recombinant retroviruses can efficiently infect dividing primary cells gene expression from integrated proviral genomes is often unstable (9). Similar problems have been encountered with long term gene expression using episomal viral vectors (10).

More recently *in vivo* delivery of plasmid DNA containing antigen genes under the control of viral promoters has been used to elicit humoral and cell mediated immune responses in experimental animal models (11). It is not yet clear what properties the ideal mammalian expression vector for DNA vaccination should have in order to elicit an effective immune response. Many currently used viral promoters do not direct high levels of gene expression in professional antigen presenting cells. Thus a promoter which can drive expression in macrophages and other cell lines where CMV gives poor expression, e.g. prostate cancer cells, would be desirable for both genetic vaccination and gene therapy.

It is an object of the present invention to provide alternatives to the currently used viral promoters.

In accordance with the present invention there is provided a (novel) DNA construct comprising a transcriptional regulatory sequence operatively linked to a (heterologous) gene of interest which sequence comprises a polynucleotide derivable from the (wild type) eIF4A1 gene promoter or fragment thereof.

In accordance with a further aspect of the present invention there is provided a novel DNA construct comprising a transcriptional regulatory sequence operatively linked to a gene of interest which regulatory sequence comprises a polynucleotide derivable from the eIF4A1 gene promoter or fragment thereof and at least one intron sequence of the eIF4A1 gene.

In accordance with a further aspect of the present invention there is provided a novel DNA construct comprising a transcriptional regulatory sequence operatively linked to a heterologous gene of interest which regulatory sequence

comprises a polynucleotide derivable from the eIF4A1 gene promoter or fragment thereof and a polynucleotide derivable from at least one intron sequence of the eIF4A1 gene wherein the intron sequence is selected from the group consisting of; intron 1, 2, 3, 5, 6, 7, 9.

In accordance with a further aspect, there is provided a host cell comprising (harbouring) a DNA construct as hereinbefore described.

10 In accordance with a further aspect, there is provided a process for the production of a protein of interest, which process comprises the step of culturing said cells as hereinbefore described.

15 In accordance with another aspect, there is provided a DNA vaccine comprising the construct as hereinbefore described. Methods for the treatment, including prophylactically where appropriate, of diseases or disorders comprising the step of administering said vaccine are also provided. Gene therapy methods comprising the step of administering said construct are also provided.

20 The present invention provides DNA constructs that are capable of expressing a gene of interest over a longer time period than provided for by the viral promoters such as the human CMV promoter. Such expression characteristics are particularly beneficial where long term expression is required such as in gene therapy, vaccination treatments and in the commercial production of proteins.

25 In preferred embodiments, the construct of the present invention is non-chromosomal e.g. a phage, plasmid, virus, minichromosome or transposon. Of these, plasmid is particularly preferred. The transcriptional regulatory sequence comprises a polynucleotide derivable from eIF4A1 promoter or fragment thereof. SEQ.I.D.NO:38 sets forth the sequence of the human eIF4A1 promoter from position -526. By the term "derivable" it is intended to convey a source not only in the sense of it being the physical source for the material but also to define material which has structural and/or functional characteristics which correspond to those materials but which does not originate from the reference source. The polynucleotide is preferably derived from a mammalian source,

30

35

particularly murine, rattus or human, preferably human. Fragments of the eIF4AI promoter may be used in place of, or in addition to the full length promoter sequence so long as they retain the biological characteristic of a promoter when incorporated into constructs of the present invention. Indeed, the present inventors have demonstrated that such fragments may be obtained from the full length eIF4AI promoter sequence. Accordingly, such fragments include -526EIF, -371EIF, -271EIF, -193EIF, -120EIF, -98EIF, -69EIF and -40EIF. Variants of the wild type eIF4AI promoter sequence are also envisaged. Such variants maybe naturally occurring variants which may have a substitution, deletion or insertion of one or more bases. Variants also include non-naturally occurring variants in which one or more bases have been added, substituted, inserted, deleted, rearranged or modified yet retain promoter characteristics. Also encompassed within the scope of the present invention are variants having at least 90% identity with the eIF4AI promoter or fragment thereof, e.g. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even 99% identity.

In preferred forms, the transcriptional regulatory sequence comprises a polynucleotide derivable from the eIF4AI promoter or fragment thereof and at least one intron (or fragment thereof) derivable from the eIF4AI gene. In particular, it is preferred that the intron is derivable from intron 1,2,3,5,6,7 or 9. Of these it is particularly preferred that the polynucleotide is derived from intron 1 of the eIF4AI gene. It is preferred that the intron polynucleotide is derived from a mammalian source, e.g. murine, rattus or human, preferably human. Variants of the intron sequence in which one or more bases have been added, substituted, inserted, deleted, rearranged or modified yet retain enhancer characteristics are also envisaged. Variants of the transcriptional regulatory sequence having at least 90% identity, e.g. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even 99% are also provided. The present inventors have demonstrated advantage in utilising more than one intron derivable from eIF4AI gene. Thus, constructs may comprise a transcriptional regulatory sequence comprising a polynucleotide derivable from the eIF4A promoter or fragment thereof and a plurality of eIF4AI gene introns. The additional intron sequence may be the same or different from the preceding intron. It is preferred that the polynucleotide comprises the eIF4AI promoter sequence or fragment thereof and eIF4AI intron sequence or fragment thereof arranged in tandem in forward

or reverse orientation. The intron sequence and promoter sequence may be co-terminus or spaced apart. The intron sequence may be upstream or more preferably downstream (in terms of reading frame) of the eIF4A promoter sequence. Chimaeric constructs e.g. one in which the polynucleotide comprises the eIF4A promoter or fragment thereof derived from a first species and the intron sequence derived from a second species are also envisaged. Preferably, the promoter sequence is produced by recombinant means, such techniques being standard and well known to those skilled in the art.

Constructs of the present invention may further comprise other elements such as a terminator sequence and a selectable marker, bacterial origin of replication, antibiotic resistance gene and a signal peptide gene for secretion if necessary.

Constructs of the present invention are preferably incorporated into a host cell for gene expression although cell-free translation systems are not excluded.

The incorporation of the constructs may be achieved by methods well known to those skilled in the art, e.g. P1 transduction. Suitable host cells maybe prokaryotic or eukaryotic, preferably eukaryotic, even more preferably mammalian. Host cells may be fully differentiated, pluripotent stem cells or other precursor cells. The present invention is particularly advantageous in directing

high level persistent expression of a gene of interest in professional antigen presenting cells such as macrophages and dendritic cells and other cells that have been shown to be refractory to high level, persistent gene expression by viral promoters e.g. prostate and colorectal cancer cells.

Host cells transformed by constructs of the present invention may be used in the commercial production of proteins. Generally, a fermentation method is employed which involves submerging the cells in a culture medium contained within a suitable vessel. Following culturing at appropriate conditions, proteins secreted by host cells maybe recovered from the culture medium by standard techniques known to those skilled in the art. It is preferred that the protein is recovered to homogeneity. In addition transformed host cells of the present invention maybe utilised in therapeutic strategies for replacing or compensating for cell loss. For example, mammalian host cells for transplantation (which maybe autologous or allogenic or less preferred xenogeneic) maybe transformed *ex vivo* with a gene construct of the present invention in which the

gene of interest encodes dopamine for the treatment of Parkinson's disease although other cell loss diseases or disorders which may benefit from the present invention will be readily apparent to those skilled in the art. Viruses, particularly retroviruses and adenoviruses, incorporating the transcriptional regulatory sequence of the present invention are also envisaged. Embodiments in which the gene of interest encodes a prodrug converting enzyme are also provided.

Of particular interest is the use of the constructs of the present invention in DNA vaccines and gene therapy. Examples of DNA vaccines that may benefit from the present invention include tumour vaccines, hepatitis B and C, HIV, tuberculosis, HPV and HSV vaccines and vaccines directed at modifying chronic inflammatory reactions, such as MS, asthma, RA and Alzheimers, or directed at other biological pathways, such as vaccines for contraception or drug addiction.

For gene therapy treatments, constructs may be incorporated into a carrier such as liposomes. Typically such liposomes are cationic for example imidazolium derivatives (WO95/14380), guanidine derivatives (WO95/14381), phosphatidyl choline derivatives (WO95/35301), piperazine derivatives (WO95/14651) and biguanide derivatives. The construct may comprise a gene of interest such as CTFR or erythropoietin gene operatively linked to the promoter sequence. Thus a method of correcting or compensating for a disease or disorder whose etiology is characterised by a genetic aberration (such as cystic fibrosis) is provided, which method comprises the step of administering to a mammalian patient in clinical need thereof a therapeutically effective amount of the construct, preferably incorporated into a carrier. In a particularly advantageous use, constructs of the present invention may be used in driving high level persistent gene expression in avelolar macrophages.

The promoter sequence of the present invention is operatively linked to a gene of interest. Genes of interest include genes encoding for therapeutic or non-therapeutic proteins. Therapeutic proteins include those whose large scale commercial production is hampered by the prohibitive cost of current techniques. The gene of interest may encode a protein which is heterologous with respect to the host cell, i.e. not normally expressed in the host cell. By way of illustration,

genes encoding for proteins such as interferon- β , factor VIII, erythropoetin, growth factors and cytokines or therapeutically effective fragments thereof, are all examples of genes of interest. Medicaments, particularly pharmaceutical compositions, comprising therapeutic proteins produced according to the present invention are also provided. The elf4A promoter is active in all cell types, i.e. it is a ubiquitously active promoter, and gives sustained high level expression in all cell types.

In accordance with further aspects of the present invention, isolated forms of introns 1 (SEQ.I.D.NO:31), 2 (SEQ.I.D.NO:32), 3 (SEQ.I.D.NO:33), 5 (SEQ.I.D.NO:34), 6 (SEQ.I.D.NO:35), 7 (SEQ.I.D.NO: 36) and 9 (SEQ.I.D.NO:37) are provided. By the term "isolated" we mean that the nucleic acid as described herein exists in a physical milieu distinct from that in which it occurs in nature. For example, the nucleic acid may be isolated with respect to one or more materials it is associated with in the natural state. Thus in accordance with the present invention, there is provided an isolated polynucleotide comprising (or consisting essentially of) the sequence as set forth in SEQ.I.D.NO:31 or 32 or 33 or 34 or 35 or 36 or 37 or variant thereof. A recombinant DNA construct comprising a transcriptional regulatory sequence which regulatory sequence comprises a polynucleotide derivable from the isolated polynucleotide as described herein is also provided. Isolated polynucleotides as identified herein maybe used as enhancer elements in transcriptional regulatory sequences found in recombinant DNA constructs. In other aspects, a recombinant DNA construct comprising an transcriptional regulatory sequence operatively linked to a heterologous gene of interest which regulatory sequence comprises (or consists essentially of) a polynucleotide having a sequence as set forth in SEQ.I.D.NO:38 or variant thereof preferably further comprising a sequence as set forth in any one of SEQ.I.D.NO:31, 32, 33, 34, 35, 36, 37 or variant thereof is provided.

In other aspects there is provided an isolated polynucleotide having a sequence as set forth in fig.9 at positions -2102 to -1082 or variant thereof.

There is also provided an isolated polynucleotide having a sequence as set forth in fig.9 at positions -1107 and -505 or variant thereof.

Suitable techniques for introducing the naked polynucleotide or vector into a patient include topical application with an appropriate vehicle. The naked polynucleotide or vector may be present together with a pharmaceutically acceptable excipient, such as phosphate buffered saline (PBS). One technique involves particle bombardment (which is also known as 'gene gun' technology or Particle Mediated DNA Delivery and is described in US Patent No. 5371015). Here inert particles (such as gold beads) are coated with a nucleic acid, and are accelerated at speeds sufficient to enable them to penetrate a surface of a recipient (e.g. skin), for example by means of discharge under high pressure from a projecting device. (Particles coated with a nucleic acid molecule of the present invention are within the scope of the present invention, as are devices loaded with such particles.) Other methods of administering the nucleic acid directly to a recipient include ultrasound, electrical stimulation, electroporation and microseeding which is described in US-5,697,901.

A nucleic acid sequence of the present invention may also be administered by means of specialised delivery vectors useful in gene therapy. Gene therapy approaches are discussed for example by Verme *et al*, Nature 1997, **389**:239-242. Both viral and non-viral systems can be used. Viral based systems include retroviral, lentiviral, adenoviral, adeno-associated viral, herpes viral and vaccinia-viral based systems. Non-viral based systems include direct administration of nucleic acids and liposome-based systems.

The constructs of the invention may be administered as pharmaceutical compositions, which are typically administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

The pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific indication or indications. In general, the compositions are administered in an amount of at least about 1 µg/kg body weight. In most cases they will be administered in an amount not in excess of about 8 mg/kg body weight per day. Preferably, in most cases, dose is from about 1 µg/kg to about 1 mg/kg body weight, daily. It will be appreciated that

optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like.

5 In therapy or as a prophylactic, the construct may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

10 Alternatively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible
15 conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.

20 For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 1 $\mu\text{g/kg}$ to 10 mg/kg , typically around 1 mg/kg . The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of
25 the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

30 The present invention will now be illustrated by way of example only. It should be understood that these represent preferred embodiments of the invention. Various modifications and changes within the spirit and scope of the invention will be apparent to those skilled in the art.

Brief description of drawings.

Fig.1: illustrates the organisation of the human eIF4A1 gene. Coding sequence exons of the eIF4A1 and CD68 genes are represented by black boxes, introns by white boxes and 3' untranslated regions by shaded boxes. The position of Alu I repeat sequences is shown by horizontal arrows below the line. Vertical lines with arrowheads denote the transcription start sites of the two genes, poly A addition sites are represented by the symbol pA⁺. Hatched boxes delineate the regions of the human eIF4A1 gene sequence which share homology with the murine eIF4A1 promoter and the position of the CpG rich methylation free island within intron 1. White and black boxes represent the positions of promoter fragments, (PCR A and PCR B respectively), assayed for transcriptional activity in fig.4.

Fig.2: DNA sequence of the promoter and exon 1 of the human eIF4A1 gene. DNA sequences are numbered with the putative transcription site denoted as +1. Potential transcription factor binding sites are underlined. The amino acids encoded by exon 1 are shown. eIF4A1 gene sequence was determined by DNA sequencing of the cosmid clone cosCD68C1 (Jones, E., Quinn, C.M., See, C.G., Montgomery, D.S., Ford, M.J., Kolble, K., Gordon, S., and Greaves, D.R. (1998), Genomics 53: 248-250).

Fig.3: Mapping the transcriptional regulatory sequences of the eIF4A1 promoter. The indicated luciferase reporter plasmids were introduced into CHO, 293 and RAW264.7 cells along with a beta-galactosidase reporter gene plasmid (pcDNA Beta gal) as described below. Cell lysates were prepared 16 hours after transfection and assayed for luciferase and beta galactosidase enzyme activities. Cell lysates were diluted in cell lysis buffer to ensure that all luciferase assays were within the linear range of the enzyme assay. The error bars represent the standard error of the mean of two independent transfection experiments.

Fig.4: Transcriptional regulatory sequences in eIF4A1 5' flanking sequence. Plasmid DNAs of the indicated plasmids (20µg) were introduced into RAW264.7 cells by electroporation along with plasmid DNA (2µg) for a beta galactosidase expression vector (pcDNA3 Beta gal). A and A', B and B' represent forward and reverse orientations respectively of the PCR fragments shown in fig.1. Cell

lysates were prepared 16 hours after transfection and assayed for luciferase and beta galactosidase enzyme activities. Luciferase enzyme activities are expressed relative to the luciferase activity obtained with the plasmid -40eIF luc transfected in the same experiment. Similar results were obtained in two independent experiments.

Fig.5: eIF4A1 directs high-level expression in macrophage cell lines. Panel A. Plasmid DNAs of the indicated plasmids (20 μ g) were introduced into RAW264.7 cells by electroporation along with plasmid DNA (2 μ g) for a beta galactosidase expression vector (pcDNA3 Beta-gal). Cell lysates were prepared 24 hours after transfection and assayed for luciferase and beta-galactosidase enzyme activities. Error bars represent the standard error of the means of two independent experiments.

Panel B. RAW cells were electroporated with the plasmid hCMVluc or -271eIF-IVS1 and the co-reporter plasmid pcDNA3 Beta-gal. Cells were harvested at 16, 24, 36, 48, 72 and 96 hours post transfection and cell lysates assayed for luciferase activity. Relative luciferase activities are given as a percentage of the value obtained at 16 hours normalised for beta-galactosidase activity at 16 hours. Similar results were obtained in two independent experiments.

Panel C. CHO cells were transfected with the plasmid hCMVluc or -271eIF-IVS1 and the co-reporter plasmid pcDNA3 Beta-gal. Cells were harvested at 16, 24, 40 and 48 hours post transfection and cell lysates assayed for luciferase activity. Relative luciferase activities are given as a percentage of the value obtained at 16 hours normalised for beta-galactosidase activity at 16 hours. Similar results were obtained in two independent experiments.

Fig.6: The plasmid -40 IVS1 (x1) contains one copy of eIF4A1 gene intron 1 cloned downstream of the -40 eIF4A1 promoter fragment in pGL3Basic and plasmid -40 IVS1 (x2) contains two copies of eIF4A1 gene intron 1 cloned downstream of the -40 eIF4A1 promoter. The plasmid pGL3Control contains the SV40 promoter and enhancer sequences cloned into the luciferase reporter plasmid pGL3Basic.

The indicated plasmid DNAs were introduced into the murine macrophage cell line RAW 264.7, human 293 cells and Chinese Hamster Ovary (CHO) cells along with a beta-galactosidase co-reporter plasmid (pcDNA3 Beta-gal). Cells were harvested 16 hours post transfection and cell lysates assayed for luciferase and beta-galactosidase enzyme activities. Normalised luciferase activities are expressed as fold induction compared to the promoterless vector pGL3Basic.

Fig.7 The eIF4A promoter and intron 1 are active in cancer cell lines. Luciferase reporter plasmids were introduced into (A) LNCaP (human prostate cancer) and (B) Cos-1 (African green monkey kidney), cells by electroporation and into (C) WiDr (human colorectal cancer) and (D) SKOV-3 (human ovarian cancer) using lipofectin. Cell lysates were prepared 48 hours post transfection and luciferase assays were performed and standardized by total protein content. All experiments were repeated in triplicate and showed similar values, but in each case a representative single experiment is shown.
(HSV1Tkmin = minimal thymidine kinase promoter from Herpes Simplex Virus 1).

Fig.8. The eIF4A promoter and intron 1 direct gene expression in vivo in mouse muscle. Luciferase reporter plasmids (50µg) were injected into the quadriceps muscle of C57Bl.6 mice. Muscles were removed after 72 hours and assayed for luciferase activity and the values standardized by protein content. Data is the mean of five animals. (-40EIF IVS1 A = one copy of intron 1, -40eIF4A IVS1 B = two copies of intron 1).

Fig.9:

DNA sequence of 5.318 kb upstream of the human eIF4A gene.

Figure 9

This sequence starts from the 5' Not I site of cosmid cos CD68C1, at -5280, where the transcriptional start site of the human eIF4A gene is +1, (Figure 2). It also includes the promoter and exon 1 sequence shown in Figure 2 and ends at the final base of exon 1, (+37). Regions of homology to Alu I repeat sequences or to the mouse eIF4A gene and surrounding sequences are underlined,(see Figure 1). The regions cloned and assayed for transcriptional activity as PCR A (-

2102 to -1082) and PCR B (-1107 to -505) are highlighted in bold or italics, respectively, (see Figures 1 and 4).

Fig.10: Comparative luciferase activity of eIF4A and CMV promoter expression plasmids upon transient transfection into MK cells.

Fig. 11: Time course of promoter activity in MK cells.

Fig. 12: Efficacy of CMV and -271Eif-IVS1 promoters in particle mediated DNA delivery. Serum IgG response (1000 times dilution).

Fig. 13: Efficacy of CMV and -271eIF-IVS1 promoters in particle mediated DNA delivery. Serum IgG response 2 weeks post boost.

Materials and Methods

DNA sequence of the human eIF-4A1 gene. Restriction enzyme fragments of the recombinant cosmid cosCD68C1 containing the human eIF4A1 gene were subcloned into pBluescript SK-. DNA sequence was determined on both strands of the plasmid and cosmid templates using a Dye Terminator sequencing kit (ABI Perkin Elmer).

Reporter gene plasmids. Fragments of the human eIF4A1 promoter were PCR amplified to generate a 5' promoter deletion series using cosmid cosCD68C1 as template. Forward PCR primers included a Kpn I site and the reverse primer included a Hind III site, PCR products were digested with Kpn I and Hind III and cloned into the multiple cloning site of the luciferase reporter vector pGL3 Basic (Promega). Forward primers used were:

eIF-526 5' ATCTGGTACCCTACGATATCGCTGTTGATTTC (SEQ.I.D.NO:1),
 eIF-371 5' ATCTGGTACCTGGAGGCTGAGACCTCGCC, (SEQ.I.D.NO:2)
 eIF-271 5' ATCTGGTACCATGGCTGCCAGGCCTCGAGG, (SEQ.I.D.NO:3)
 eIF-193 5' ATCTGGTACCGGCTGCGGGGCGGGCC, (SEQ.I.D.NO:4)
 eIF-120 5' ATCTGGTACCTAGGAACCTAACGTCATGCCG, (SEQ.I.D.NO:5)
 eIF-98 5' ATCTGGTACCGTTGCTGAGCGCCGGCAGGC, (SEQ.I.D.NO:6)
 eIF-69 5' ATCTGGTACCAAACCAATGCGATGGCCGG (SEQ.I.D.NO:7) and

eIF-40 5' ATCTGGTACCCGGGCGCTCTATAAGTTGTCG (SEQ.I.D.NO:8). The reverse primer used was

5' ATATAAGCTTTGATCCTTAGAACTAGGGC (SEQ.I.D.NO:9).

Regions of the human eIF4A1 5' flanking region which show homology to the mouse eIF-4A1 5' flanking sequence were PCR amplified using the primers

eIFBF 5' ATCTGGTACCGACTGGATTTCACCAG (SEQ.I.D.NO:10) and

eIFBR 5' ATCTGGTACCACCCAGGGCCACAGG (SEQ.I.D.NO:11). The region of non-homology with the murine eIF-4A1 5' flanking region was PCR amplified using the primers eIFAF 5' ATCTGGTACCTGTGGCCCTGGGTGG

(SEQ.I.D.NO:12) and

eIFAR 5' ATCTGGTACCGGAAATCAACAGCGATATCGT (SEQ.I.D.NO:13).

PCR products were digested with Kpn I and cloned in both orientations into the Kpn I site of eIF-40luc to give the plasmids B'eIF-40luc, B'eIF-40luc, A'eIF-40luc and A'eIF-40luc.

Introns of the eIF4A1 gene were PCR amplified with the following primers:

IVS1 F 5' ATCTAAGCTTCCCGGTAAGAAAGGCATTTG (SEQ.I.D.NO:13),

IVS1R 5' ATCTAAGCTTGGATCTGTTGGTTTAAAGCAT, (SEQ.I.D.NO:14)

IVS2F 5' ATCTAAGCTTGTGACCCCGAAGGCGTCATCGAGGTGA (SEQ.I.D.NO:15),

IVS2R 5' ATCTAAGCTTGAATTCTAGGGGATGCAAAGA (SEQ.I.D.NO:16),

IVS3F 5' ATCTAAGCTTGTATCAAGGGTGAGACC (SEQ.I.D.NO:17),

IVS3R 5' ATCTAAGCTTCATAACCTAAACAAATAAATT (SEQ.I.D.NO:18),

IVS4F 5' ATCTAAGCTTCTCAGCAGGTAAGAGTGG (SEQ.I.D.NO:19),

IVS4R 5' ATCTAAGCTTGAATTCCTTCTGTATCTGAGCAG (SEQ.I.D.NO:20),

IVS5F 5' ATCTAAGCTTTGCTGGTTTCTCTCTGG (SEQ.I.D.NO:21),

IVS5R 5' ATCTAAGCTTGAATTCGGGCTAGAGAAGAAAAA (SEQ.I.D.NO:22),

IVS6F 5' ATCTAAGCTTCCCAGGTGAGGGCAGT (SEQ.I.D.NO:23),

IVS6R 5' ATCTAAGCTTGAATTCAGCAAACTACCTAGTGGA (SEQ.I.D.NO:24),

IVS7F 5' ATCTAAGCTTCGTGGAACGAGAGGTGG (SEQ.I.D.NO:25),

IVS7R 5' ATCTAAGCTTGAATTCCTTCCACTCCTGGAGGTT (SEQ.I.D.NO:26),

IVS8F 5' ATCTAAGCTTTGGTGTGTTTGCCCCCT (SEQ.I.D.NO:27),

IVS8R 5' ATCTAAGCTTGAATTCTGCTGGAAGAGAAAACAAA (SEQ.I.D.NO:28),

IVS9F 5' ATCTAAGCTTCTGACCTGCTGGTGAGTAG (SEQ.I.D.NO:29) and

IVS9R 5' ATCTAAGCTTGCCTCTGGCCTACGTCAAGAAAG (SEQ.I.D.NO:30). PCR fragments were digested with HindIII and cloned into the unique HindIII site of plasmid eIF-40luc, which lies 3' of the transcription initiation site of the eIF4A1 gene promoter. Restriction mapping and DNA sequencing was used to identify plasmids containing introns in the correct orientation. Introns 1, 2 and 3 were excised with Hind III, rendered blunt ended by treatment with Klenow DNA polymerase and cloned into the KpnI site of -40eIFluc to give the plasmids IVS1eIF-40luc, IVS2eIF-40luc and IVS3eIF-40luc in which the introns are placed 5' of the eIF4A1 minimal promoter. The plasmid pGL3 Control contains 195bp of the SV40 promoter cloned 5' of the luciferase reporter gene and 244bp of the SV40 enhancer cloned 3' of the luciferase reporter gene (Promega). The plasmid hCMVluc was constructed by cloning the Nru I / Hind III CMV promoter fragment from pcDNA3 (InVitrogen) into the Sma I / Hind III polylinker sites of pGL3 Basic (Promega). The 200bp Herpes Simplex Virus 1 thymidine kinase promoter was PCR amplified and cloned into KpnI/Bg II sites of pGL3 Basic (Promega). The plasmid pcDNA3 Beta gal (14) contains the *E.coli* lacZ gene cloned into the mammalian expression vector pcDNA3 (InVitrogen). Plasmid DNA for transfection was prepared from 500ml cultures of *E.coli* grown overnight in LB broth containing 100µg ampicillin (Sigma) using a standard NaOH/SDS lysis protocol and centrifugation in CsCl ethidium bromide gradients (12).

Mammalian cell culture and transient transfection. The murine macrophage cell lines RAW264.7 and P388.D1, the murine B cell line A20 and the human erythroleukaemic cell line K562 and the human prostate cancer cell line, LNCaP were maintained in RPMI 1640 medium (Life Technologies) supplemented with 10% heat inactivated foetal calf serum (FCS) (Sigma, St. Louis, MO), 100 units ml⁻¹ penicillin, 100 µg ml⁻¹ streptomycin and 2mM glutamine. CHO K1 and SKOV-3 cells were maintained in Ham's F-12 medium and 293 cells WiDr and COS-1 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FCS, antibiotics and glutamine. All cells were grown at 37°C in a humidified incubator in 5% CO₂/air mixture.

RAW264.7, P388.D1, A20 and K562 LNCaP and COS-1 cells were transfected by electroporation. Briefly, cells were grown to confluence in T175 flasks,

harvested in Phosphate Buffered Saline (PBS), washed once with PBS and resuspended in Optimem 1 serum free medium (Life Technologies) for RAW cells or RPMI 1640 (no FCS). Aliquots of 2×10^7 cells (0.5ml) were mixed with 20 μ g luciferase reporter plasmid DNA and 2 μ g pcDNA3 β -galactosidase plasmid DNA, added to a 0.4cm electrode gap electroporation cuvette (BioRad, Hercules, CA) and shocked in a BioRad GenePulser (300V, 960 μ FD) at room temperature. Cells were recovered immediately into 10ml of pre-warmed medium and plated into 9cm diameter tissue culture petri dishes (Nunc).

CHO and 293 cells were grown to 70-80% confluence in 9cm petri dishes, washed twice with Optimem before addition of 5ml of plasmid DNA:cationic lipid complex (5 μ g DNA: 50 μ g Lipofectamine (Life Technologies) in Optimem). After 4-6 hours incubation the medium was aspirated, cells were washed twice with PBS and recovered into complete medium for 16 hours before analysis. SKOV-3 and WiDr cells were similarly transfected using 5 μ g DNA, 50 μ l lipofectin (Life Technologies)

Reporter gene assays Transfected cells were harvested in 500 μ l Reporter Lysis Buffer (Promega) and lysed with one cycle of freeze thaw. Cell lysates were assayed for β -galactosidase enzyme activity using the colorimetric substrate chlorphenolred β -D-galactopyranoside (CPRG, Boehringer Mannheim) in a 96 well plate assay in 50mM potassium phosphate buffer (pH7.3) with 2mM MgCl₂. Enzyme activity was determined by spectrophotometry at 570nm after 30 minutes incubation at 37°C using dilutions of purified E.coli β -galactosidase enzyme (Sigma) to generate a standard curve. Luciferase enzyme activity was determined using a Luciferase Assay Kit (Promega) and a Berthold Instruments LB9501 luminometer. All luciferase enzyme assays using transfected cell extracts were within the linear range of the assay.

In vivo luciferase assays.

Luciferase reporter plasmids, (50ug), were injected into the quadriceps muscles of C57Bl/6 mice. Muscles were removed after 72 hours and disrupted in 500ul of reporter lysis buffer, (Promega), using an IKA Labortechnik Ultra turrax T8 polytron. Luciferase enzyme activity was determined using a luciferase assay kit, (Promega) and a Dynatech Laboratories ML3000 luminometer. Total protein content was measured in a 96 well format using a Pierce Coomassie Plus

Protein Assay Reagent against a standard curve using a Molecular Devices Spectra Max 250 plate reader.

Results

5 eIF4A1 gene organisation

We have shown previously that the macrophage restricted CD68 gene lies 669bp 3' of the gene encoding the ubiquitously expressed translation initiation factor eIF-4A1 gene on chromosome 17p13 (13,14). We determined the DNA sequence of 11.9kb of CD68 5' flanking sequence and showed that the human
10 eIF4A1 gene is 6.2kb in size and contains ten introns shown schematically in Fig.1. The position of the eIF4A1 gene introns and their sizes are listed in Table 1.

Intron	Size	Sequence
Intron 1	1397 bp	AGGATTCCCGgtaagaaagg...aaaccaacagATCCAGAGAC
Intron 2	226 bp	CGTCATCGAGgtgagactgg...catcccctagAGTAACTGGA
Intron 3	440 bp	TGTATCAAGGgtgagacctc...attgttttagGTTATGATGT
Intron 4	1264 bp	GGCTCAGCAGgtaagagtgg...ctctgctcagATACAGAAGG
Intron 5	363 bp	AGATACCTGTgtgagtaatt...tcttctctagCCCCCAAATA
Intron 6	179 bp	CAACACCCAGgtgagggcag...ttccactagGTAGTTTTGC
Intron 7	81 bp	GGAACGAGAGgtggggccca...caacctccagGAGTGGAAGC
Intron 8	120 bp	ATCCGCCATGgtgtgtttgc...tctcttcagCATGGAGATA
Intron 9	248 bp	TGACCTGCTGgtgagtagag...cttgacgtagGCCAGAGGCA
Intron 10	96 bp	ATATCCACAGgtaagcgtag...tgtttccagAATCGGTCGA

15 Table 1: eIF4A1 intron sizes are given in base pairs. The exon/ intron boundary sequences are shown with the exon sequences in upper case and the intron sequences in lower case.

20 The first intron of the eIF4A1 gene contains many CpG dinucleotides and has many features of a methylation free island. An analysis of the first intron DNA sequence revealed the presence of many potential binding sites for mammalian transcription factors. eIF4A1 intron 1 contains three consensus binding sites for

Sp1, two C/EBP β sites, two binding sites for each of the ets factors Elk-1 and c-ets-1 and 8 binding sites for the transcription factor GATA-1. The 440 bp third intron of the eIF4A1 gene contains a 35bp region containing four overlapping consensus binding sites for GATA 1 and three for GATA2 (Fig. 2 and data not shown).

eIF4A1 promoter sequence

Comparison of the DNA sequence of the human eIF4A1 gene 5' flanking region with the published sequence of the murine eIF-4A1 gene sequence (15) revealed a 300bp region showing ~85% sequence homology with the mouse eIF-4A1 gene proximal promoter. This region contains a canonical TATA box sequence at position -32 relative to the putative transcription start site (16), CCAAT box sequences at positions -65, -141 and -190 and consensus binding sites for the transcription factor Sp1 at positions -51, -74, -177 and -348, (Fig. 2). Homology with the murine eIF-4A1 promoter sequence ends at position -475 but homology with the murine promoter continues at position -1110 and extends for a further 254 bp to the end of the published murine eIF-4A1 sequence. The 638 bp region of non-homology with the murine promoter (positions -1109 to -471) contains an extended dinucleotide repeat sequence (AT)₃₈, alternating AT repeats have been shown to be present as interspersed repetitive elements in several eukaryotic genomes (17). Analysis of the eIF4A1 5' flanking sequence revealed the presence of AluI interspersed repeats at positions -4588 and -3722 relative to the eIF4A1 transcription start site (Fig.1).

eIF4A1 promoter analysis

A 5' deletion series of the eIF4A1 gene promoter was constructed in the luciferase vector pGL3 Basic and plasmid DNAs were introduced into a range of mammalian cell lines by transient transfection. A DNA fragment extending from -526 to + 15 of the eIF4A1 gene directs high-level luciferase reporter gene expression in the epithelial cell lines CHO and 293 and in the murine macrophage cell line RAW 264.7 (Fig. 3A-C). In CHO cells the maximal level of luciferase expression is obtained with plasmid -526eIFluc and the level of expression is similar to that obtained with the SV40 enhancer/promoter vector pGL3 Control (Fig. 3A). In 293 cells the maximal level of luciferase expression is obtained with the -371eIFluc plasmid with the level of luciferase expression

being 18 times that obtained with the SV40 enhancer/promoter (Fig. 3B). The –40elFluc plasmid which contains only the TATA box and the –69elFluc plasmid which contains a CCAAT box, an Sp1 site and the TATA box give levels of reporter gene expression only slightly higher than that seen with the reporter gene vector alone (pGL3 Basic). The –98elFluc plasmid which contains an additional 29bp of eIF4A1 promoter sequences contains an AP-2 site and directs high-level gene expression in all three cell lines tested. The –120elFluc plasmid directs similar levels of reporter gene expression in 293 cells but significantly reduced levels of reporter gene expression are seen in CHO and RAW 264.7 cells. Addition of eIF4A1 sequences 5' of –120 restores high levels of reporter gene expression.

PCR primers were designed to amplify human eIF4A1 gene sequences 5' of position –1110 that show homology with the murine eIF-4A1 promoter. A 1018 bp fragment containing eIF4A1 gene sequences extending from position –2098 to –1080 was cloned in both orientations 5' of the eIF4A1 minimal promoter in the reporter gene vector –40elFluc to give the plasmids B'eIF-40luc and B'eIF-40luc. A 597bp region of the human eIF4A1 promoter that shows no homology with the murine eIF-4A1 promoter was cloned into the reporter gene vector –40elFluc to give the plasmids A'eIF-40luc and A'eIF-40luc. In CHO cells the plasmids B'eIF-40luc and B'eIF-40luc give levels of luciferase expression only twofold higher than that obtained using the eIF4A minimal promoter (Fig. 4A). In 293 cells the same plasmids enhance expression between 4 and 6-fold (Fig. 4B) while in RAW cells expression is enhanced 5-fold (data not shown). By contrast the region of non-homology with the murine eIF-4A1 promoter present in plasmids A'eIF-40luc and A'eIF-40luc enhances expression up to 27-fold in CHO cells, 13-fold in 293 cells and 5-fold in RAW cells (Fig 4).

Analysis of transcriptional regulatory elements in eIF4A1 gene introns

eIF4A1 intron 1 contains a methylation free island and potential binding sites for several ubiquitous transcription factors such as Sp1, c-ets1 and Elk-1. Potential transcription factor binding sites are found in other introns of the eIF4A1 gene. We prepared a series of luciferase reporter plasmids in which the first nine introns of the eIF4A1 gene were cloned downstream of an eIF4A1 minimal promoter fragment and tested their activity in transient transfection assays. The

data are summarised in Table 2 showing the fold increase in reporter gene activity compared to the eIF4A1 minimal promoter alone (plasmid -40eIFluc).

Plasmid	K562	A20	CHO	293	P388.D1
-40eIF luc	1	1	1	1	1
-40eIF IVS1	260	52.6	29.8	51.6	482
-40eIF IVS2	10.7	7.2	2.2	19.8	5.7
-40eIF IVS3	20	12.6	3.7	26.4	4.3
-40eIF IVS4	0.4	1.9	0.6	0.8	0.6
-40eIF IVS5	7.3	9.5	5.3	14.2	2.9
-40eIF IVS6	10	5.2	4.5	14.3	2.6
-40eIF IVS7	25.3	14.7	5.5	23	6.3
-40eIF IVS8	0.1	0.1	n.d.	n.d.	0.1
-40eIF IVS9	18	8.7	3.3	9.6	2.2

5 Table 2 Effect of eIF4A1 introns on transcription from an eIF4A1 minimal promoter.

With the exception of introns 4 and 8 seven of nine eIF4A1 introns tested were shown to enhance expression when cloned downstream of the eIF4A1 minimal promoter. In all cell lines tested the greatest enhancement of expression is seen when the 1397bp first intron of the eIF4A1 gene is cloned downstream of the eIF4A1 minimal promoter. The magnitude of the observed enhancement varies from 30-fold in CHO cells to 480-fold in the murine macrophage cell line P388.D1. Introns 2, 3, 7 and 9 were able to enhance reporter gene expression more than 15-fold. However, the activity of these introns varied widely between different cell lines, for example, the 83bp eIF4A1 intron 7 enhances luciferase expression 25-fold in K562 cells but only 6-fold in CHO and P388.D1 cells.

To test if intron 1 of the eIF4A1 is able to act as a classical transcriptional enhancer a 1397bp IVS1 fragment was cloned 5' of the eIF4A1 minimal promoter in the plasmid -40eIFluc to give the plasmid IVS1eIF-40luc. Reporter gene plasmids with eIF4A1 placed 5' or 3' of the eIF4A1 minimal promoter were transfected into the murine macrophage cell line RAW 264.7. Placing eIF4A1 IVS1 3' of the eIF4A1 -40 promoter fragment enhances luciferase expression

1700-fold while placing IVS1 5' of the eIF4A1 -40 promoter enhances expression 680-fold (Table 3). Thus, eIF4A1 intron 1 sequences are able to enhance gene expression when placed 5' or 3' of the transcription start site.

	-40eIF luc	-40eIFIVS1	IVS1-40eIF	pGL3 Basic
RLU/ Beta galactosidase (x1000)	60	102000	41000	72
Fold -40eIF luc	1 x	1700 x	683 x	1.2 x

Table 3: The indicated luciferase reporter plasmids (20µg) were electroporated into RAW 264.7 cells with the beta galactosidase reporter plasmid pcDNA3 Beta gal (2µg). Cell lysates were prepared 24 hours post transfection and assayed for luciferase and beta galactosidase enzyme activities. The results shown are representative of two independent experiments.

Sustained high-level reporter gene expression in macrophages using eIF4A1 sequences

In order to develop an expression vector using eIF4A1 sequences we cloned eIF4A1 intron 1 downstream of selected eIF4A1 promoter fragments and compared the level of luciferase expression obtained with eIF4A1 sequences with SV40 and CMV enhancer/promoter sequences cloned into the same reporter gene vector. Addition of the eIF4A1 intron 1 sequence increases reporter gene expression in RAW cells from all the eIF4A1 promoter fragments tested. The level of luciferase activity obtained with the plasmid -271eIFIVS1 is equal to that obtained with the human cytomegalovirus promoter/enhancer in the plasmid hCMVluc and more than three times that obtained with the SV40 enhancer/promoter in the plasmid pGL3 Control (Fig. 5).

The data of Figure 5A were obtained with RAW cells harvested 24 hours post transfection. RAW cells were transfected with CMV and eIF4A1 promoter containing plasmids and a comparison of the level of reporter gene expression over a 96 hour period is shown in Figure 5B. The levels of CMV-driven reporter gene expression in RAW cells declines to less than 10% of initial levels 48 hours post transfection. The level of reporter gene expression obtained in RAW cells

with the -271 eIF4A1 promoter fragment and eIF4A1 intron 1 is ten fold greater than that seen using the CMV promoter/enhancer 72 hours after transfection (Figure 5B). The same experiment was performed in non-macrophage cell lines and the data of Figure 5C show a comparison of CMV- and eIF4A1-driven reporter gene expression in RAW cells. The rapid decline in CMV-driven expression seen in RAW cells is not seen in CHO cells. However the -271eIF-IVS1 plasmid gives sustained high-level reporter gene expression in CHO cells with a five fold increase in luciferase expression between 16 and 48 hours post transfection (Figure 5C).

Expression characteristics in murine macrophages using more than one eIF4A1 intron.

The plasmid -40 IVS1 (x1) contains one copy of eIF4A1 gene intron 1 cloned downstream of the -40 eIF4A1 promoter fragment in pGL3Basic and plasmid -40 IVS1 (x2) contains two copies of eIF4A1 gene intron 1 cloned downstream of the -40 eIF4A1 promoter. The plasmid pGL3Control contains the SV40 promoter and enhancer sequences cloned into the luciferase reporter plasmid pGL3Basic.

The indicated plasmid DNAs were introduced into the murine macrophage cell line RAW 264.7, human 293 cells and Chinese Hamster Ovary (CHO) cells along with a beta-galactosidase co-reporter plasmid (pcDNA3 Beta-gal). Cells were harvested 16 hours post transfection and cell lysates assayed for luciferase and beta-galactosidase enzyme activities. Normalised luciferase activities are expressed as fold induction compared to the promoterless vector pGL3Basic (see fig.6). Cloning two copies of eIF4A1 intron 1 downstream of the eIF4A1 -40 promoter gives an increase in reporter gene expression compared to the level obtained using one copy of intron 1 in all three cell lines tested. The additional increase in reporter gene expression is small in RAW cells (10%) but the second copy of eIF4A1 increases gene expression in 293 cells more than five fold.

The eIF4A promoter and intron 1 direct gene expression in vivo in mouse muscle. In vivo eIF4A promoter / intron activity has been determined in mouse muscle by injection of luciferase reporter plasmids, (Fig. 8). The -526 fragment

plus intron- 1 shows over three times the activity of the SV40 promoter / enhancer combination in this system.

The eIF4A promoter and intron 1 are active in cancer cell lines. Plasmids where luciferase expression is driven by the eIF4A promoter fragment and intron 1 (IVS-1) regions were introduced into a series of cancer cell lines: LNCaP, COS-1, WiDr and SKOV-3, (Figure 7).. Normalised luciferase activities show that the eIF4A promoter and IVS-1 are active in all cell types tested. The -271 and -526 promoter fragments are most active as in other cell types, (see Figs. 3 & 5). For example, the -526 and IVS-1 combination drives almost two fold more luciferase expression than the SV40 promoter / enhancer combination in WiDr, colorectal cancer cells and over 500 fold more expression in LNCaP, prostate cancer cell line.

By combining eIF4A1 promoter sequences with eIF4A1 intron 1 we were able to direct sustained high-level reporter gene expression in macrophages. The levels of luciferase gene expression obtained in murine macrophages using eIF4A1 vectors were three times higher than that seen with the SV40 promoter/enhancer and equal to the level of expression seen using the human CMV promoter/enhancer.

Comparison of transcriptional activity of -271eIF4A and CMV promoters in murine keratinocytes.

The inventors have also shown that the eIF4A promoter is more active in murine keratinocytes than the CMV promoter. Again this demonstrates in a cell line other than an antigen presenting cell that the eIF4A promoter is stronger than the CMV promoter. Also murine keratinocytes provide a cell line model for the cell type other than professional APCs that could contribute to the antibody response via the gene gun by expressing antigen *in vivo*. This example shows a sustained high-level reporter gene expression in keratinocytes using eIF4A1 sequences.

Mammalian cell culture.

The murine keratinocyte cell line , MK, (Weissman, B.E. and Aaronson, S. A., 1983, Cell 32, 599-606), was maintained in S-MEM, (Spinner Culture Modified

Eagle's Medium) , Life Technologies supplemented with 10% foetal calf serum , Life Technologies, 100 units/ml penicillin, 100ug/ml streptomycin, 2mM glutamine and 4ng/ml human recombinant EGF, (Sigma). Cells were grown at 37°C in a humidified incubator in 5% CO₂/air mixture.

5

Transient transfections.

MK cells were grown to 80% confluence in 6 well plates, washed twice with 1ml Optimem and transfected with 1ml of plasmid DNA: cationic lipid complex, (5ug DNA: 30ul Transfast TM, Promega), in Optimem. Cells were generally harvested 48 hours post transfection for luciferase assays or at specific time points for a time course of activity.

10

Luciferase assays.

For luciferase assays, transfected cells were harvested in 1ml Passive Lysis Buffer and luciferase activity was determined using a luciferase assay kit, (Promega) and a ML3000 plate luminometer, (Dynatech Laboratories). Total protein content was measured in a 96 well format using Pierce Coomassie Plus Protein Assay Reagent against a standard curve using a Spectra Max 250 plate reader, (Molecular Devices).

15

20

Level of transcriptional activity

The level of transcriptional activity of eIF4A1 promoter fragments combined with intron 1, (IVS-1) compared to that of the CMV promoter in murine keratinocytes, was determined. Plasmids containing the relevant promoter / intron combinations driving luciferase expression were transfected into MK cells. Luciferase activity was assayed 48 hrs post-transfection and expressed, (RLU / mg protein), as a percentage of the CMV luc plasmid, (set as 100%). The relative luciferase activity , (Fig 10), indicates that the plasmid -271eIFIVS1 directs about three times as much luciferase expression as the plasmid hCMVluc. Figure 10 represents a mean of 4 separate experiments.

25

30

Time course of promoter activity

MK cells were transfected with the plasmid hCMVluc or -271eIF-IVS1luc. Cells were harvested at 22, 31 and 48 hours post transfection and assayed for luciferase activity and total protein. Relative luciferase activities, (RLU/ mg

35

protein), are given as a percentage of the value from the first time point for each plasmid transfected. Figure 11 is a mean of 2 experiments and shows that the -271eIF-IVS1 plasmid gives sustained high-level reporter gene expression in MK cells with about a six fold increase in luciferase expression between 22 and 48 hours post transfection. Note that the rapid decline in CMV driven expression seen in RAW cells, (Fig. 5A), is not seen in MK cells.

Efficacy of -271eIF-IVS1 promoter in DNA vaccination

The following example shows that when the eIF4A promoter is driving expression of influenza nucleoprotein (NP) antigen in a particle mediated DNA delivery experiment, it produces as good or a better antibody response than an equivalent plasmid with CMV driven NP expression.

Cartridge preparation

Preparation of cartridges for particle-mediated DNA delivery (PMDD) using the Accell gene transfer device was as previously described (Eisenbraun et al DNA and Cell Biology, 1993 Vol 12 No 9 pp 791-797). Plasmid DNA was coated onto 2 μ m gold particles (DeGussa Corp., South Plainfield, N.J., USA) and loaded into Tefzel tubing, which was subsequently cut into 1.27 cm lengths to serve as cartridges and stored desiccated at 4°C until use. In a typical vaccination, each cartridge contained 0.5 mg gold coated with between 0.5 – 0.8 μ g plasmid DNA.

Animals and immunisations

Female C57Bl/6 mice, purchased from Harlan UK Ltd (Oxon, United Kingdom) or bred in our specific pathogen-free animal breeding facilities, were housed at a constant temperature and humidity, with regular 12 hour cycles of light and darkness, sterile bedding, food and water. All experiments were carried out under United Kingdom ethical guidelines. Mice were immunised between 6-8 week of age. For each immunisation, plasmid DNA was delivered to the shaved target site of abdominal skin by PMDD from two cartridges using the Accell gene transfer device at 500 lb/in² (McCabe WO 95/19799), delivering a total of between 1.0 -1.6 μ g DNA per immunisation. The DNA vaccination regime included a primary immunisation followed by one boost 6 weeks later.

tion for antibody ELISA assays
S were collected from the tail vein 1-3 days before immunisation,
after primary and 15 days after boost immunisation. Serum was
red at -20°C for subsequent antibody analyses.

ed recombinant nucleoprotein (NP) of influenza virus as a
se fusion protein for serum antibody ELISA assays
tein of influenza A virus strain PR/8/34 was cloned as
modified pUC18 vector. This was then sub-cloned as
EX-4T-3 (Pharmacia) and DNA sequence analysis
ould express an in-frame fusion with GST.

transformed with pGEX flu/NP were grown to
rotein expression was induced by the addition
ide to a final concentration of 0.1mM and
urs at 37°C . Cells were harvested by
S and the pellet resuspended in 30ml of
d by sonication at maximum amplitude
S were removed by centrifugation at
was removed and incubated with
1h at 4°C with gentle agitation.
rifugation and washed 3 times
eluted by incubation of the
ced glutathione (Sigma) in
ure. The purified protein
utathione and stored at

nologies) were
shed 4 times
ium azide).
5% BSA
S we-

buffer. After 4 further washes (as above) to remove unbound antibody, plates were incubated for 1 hour with peroxidase conjugated anti-mouse IgG antibodies (Southern Biotechnology, Birmingham, AL, USA) diluted in blocking buffer. The amount of bound antibody was determined after 4 further washes (as above) followed by addition of TMB substrate solution (T-8540, Sigma). After 30 minutes at 20°C and protected from light the reaction was stopped with 1M sulphuric acid and absorbance read at 450 nm. Titres were defined as the highest dilution to reach an OD of 0.2.

Comparison of *in vivo* effect of -271eIF4A and CMV promoters on IgG antibody response to pVAC1.PR

The NP-specific serum IgG levels were measured before immunisation, and at intervals following the primary and boost immunisations. The construct with the -271eIF4A promoter gave similar responses to those following immunisation with the construct with the CMV promoter (Fig. 12), with equivalent titres for both promoters after the boost immunisation (Fig. 13).

References

1. Nielsen, P.J., and Trachsel, H. (1988) *EMBO Journal* **7**, 2097-2105.
2. Reddy, N.S., Roth, W.W., Bragg, P.W., and Wahba, A.J. (1988) *Gene* **70**, 231-243.
3. Williams-Hill, D.M., Duncan, R.F., Nielsen, P.J., and Tahara, S.M. (1997) *Arch. Biochem. Biophys.* **338**, 111-120.
4. Jones, E., Quinn, C.M., See, C.G., Montgomery, D.S., Ford, M.J., Kölbl, K., Gordon, S., and Greaves, D.R. (1998) *Genomics* **53**, 248-250.
5. Sudo, K., Takahashi, E., and Nakamura, Y. (1995) *Cytogenet Cell Genet* **71**, 385-388.
6. Azizkhan JC, Jensen DE, Pierce AJ, Wade M (1993) *Crit Rev Eukaryot Gene Expr* **3**, 229-254
7. Bird AP (1986) *Nature* **321**, 209-213
8. Razin A. (1998) *EMBO J* **17**, 4905-4908
9. Verma, I.M. and Somia, N. (1997) Gene therapy -- promises, problems and prospects. *Nature* **389**:239-242.
10. Carlos, M.P. (1996) *Trends Genet.* **12**, 463-466.
11. Cohen AD et al. (1998) *FASEB J* **12**:1611-1626.

12. Fritsch ,Lawn and Maniatis (1989) Molecular Cloning - A Laboratory Manual. Cold Harbour Press.
13. Jones E. et al. (1998) Genomics 53: 248-250.
14. Greaves D.R et al. (1998) Genomics 54: 165-168.
- 5 15. See Reference 1.
16. Kukimoto, I. et al. (1997) Biochem. Biophys. Res. Comm. 233: 844-847.
17. Greaves, D.R. and Patient, R.K. (1985) EMBO Journal 4:2617-2626.
18. Greaves, D.R., Patient, R.K. and Lilley, D.M.J. (1985) J Mol. Biol.185 461-478.
- 10 19. Brewer AC, Enver T, Greaves DR, Allan J, Patient RK (1988) 5' structural motifs and Xenopus beta globin gene activation. J Mol Biol 199: 575-585.
20. Nan, X., Cross, S. and Bird, A. (1998) Gene silencing by methyl-CpG-binding proteins. Novartis Found Symp 214: 6-16.
- 15 21. Clarke, S. and Gordon, S. (1998) Myeloid-specific gene expression. J. Leukoc. Biol. 63:153-168.

SEQ.I.D.NO:31

GTAAGA AAGGCATTTG CAAGAGATTG TGGCTGCTTA

TTTTGCCGCC CCCTTCCGAC GGGCCCGCCG GGGGTAGCTG
AGAGGCCAC

CAGGGTTGCG GGAGAAACCG AACCGGGTGG GGGGAGGGTC
CGACTTGGAG

GGGCGAGGGG GAAGACCCAC GGCCGACGCG GCCACCAGGT
CGAGGCGGAG

GGTAGGGACA GCCCGGCTAG GGTCAGGCGT GCGAGGTCTG
TTACGAGGCC

TCGACCCGAG GCGGTGCCAT GCGCGAAGCC CCGGCGCTGA
GTGGCGAGAC

GGGGTCGCGA CCTGGCGTGG GAAAGAAAGG TGGAGGCGGC
CGCCACTATG

TGTGGCCCAG AGCCGGCAGG TCCGGTTGCC TCCCTGTGCC
GGGGGAGGGA

CGGCGCGCGG GGTTCCGGAG CATTCTGACG GTACCACTCG
CGAGAGGCGG

GGGTGCCTGG TCCTTAGATC CAGTCACTTC GTCGCGGCTA
AAACACGGGT

CGGGGAGAAG AAACCGGCCG TTCAGTGTGC TGGTTTTCTT -----
GACGGCCAGG

ACTGAGCCTA ACCCCGAGG. AGCGGCCGCG TGAGGCACCA
GGAGCCCACC

CGGCGCCGGG CGGGCGGGTC CATTTTGCCG CACAAGCCGG
GCTATTGGCA

AACTGCGGAT GGGCAGGTCC ACCTTCCTTC GGGGGTGAGC
GGCCTGAGGT

ATGGGAGGGC GACGCTACTT CGCGACGGGG GCGGGCGGGA
TGTGGATTGT

TCCATGGAGG GGTGGGAGAC RCCGCCGGGT GGTCGARGGA
GCGAGCACAT

GGTGGCCTGA GCGTTCCCC TCCCCAGTC TGCTTCGCTT
CTAAGTGTTG

TGCAATCTCC CCCTTTGCTA GCTCGGCTTG GGCTCATTGT
GCGCGAGGCC

GCCACCGCCC GCGGCCTCCC ACATCCGGGC AACGCGAGGG
GGGGGCTTCG

31

GCTGGAGGGA GTGGGGGAGG GCGCGGGCGG
GATGACGTGG GGGGAAGGGG

ATGTCCTACC CTCCGATCTG GGAGGTGAAG GGCGGGACTT
CCAGCGCGCT

GGTGCTGCGG TGGGAGGTGC ACGCGCTTGG GCTTTAAGCG
GCTGGGTCGG

GCCACGTGG ACCCGGCGGC AAGCACCACC TNTGGGCACC
GTGAGCGCGG

CGGCACGCCT GCCGGCCTGT CTTCAGAAAG GGTCACCCCC
TTATGTCGGG

GGTGGCCTGG CCTGAGCCGC TGCCTGCATG GGGCAAATGC
CTCAGTTTTA

TAGAAACTCC TCCTTTGGGT ATTTTTTGGG AGCTGGTGGG
AGTTGGATCT

GGGACAGCAG GTTGATGGCA TCATGCAGGC CACTCCTGAC
AGAGCCCGGC

TGTCAGGATT TCTGAGTGCT TCGGTCGGGC AGGGGACAAA
ACTTATGCTT

TAAACCAACA G

SEQ.I.D.NO:32

GTGAGACTGG AGAAATGGAA TTCTGTCCTC CCCCATTACA
ACTTTCAGCC

GTATAGAGTT AGAGTGGCCT CTTGATTGAT TTCCCAGATC
ATCTAGAAGC

AGCTGGTTTC CCTAAAGGGA GGAGGGTTGT AAGCTCTGAG
GCTTTTGTTA

RTASGCACCA SATTCTGTTT GCTCGGAGAC TACAGCTCAG
CTCCACCTTT

TCCATGACTC AAGCTTTAAT TTCTTTGCAT CCCCTAG

SEQ.I.D.NO:33

GTG AGA CCT CTC AGT CCC AGA TGC CCA TCT CAT ATC AGC
CAG GGA CAA AGC AAC TCC TTG TTC ATC CCA GCT TGG CTT TTG
ATC CGT GCC CAT GCC TGG TTC ATG CCT TGG ACA CAT AGG TTT
CCT TTA AAG AGG TGG TAT TGT AGC CAG CTT ATA TTT GCA TCT
ACA GCC ATG TTT CTA GTC CAG CTT GGT GTG CAA TAC TAG ATG
AGT TAA TAA CTG GTC CTT GTT TCT GAT CTG GTT CCC ATT GTG
TAA CTG TGT TGA TTG GGA AGG TAG TTT GTG AGC CAT GAA ATG
CTT GGT TCA TTG GTT GCT TAT TGA CCT CAT TAA CCT AGG ACT
TGA ATA TCC CAA AGG GTA TGC TCT TTA CCA CAT TCA ACT CCT
AAT TTA TTT GTT TAG

SEQ.I.D.NO:34

GTG AGT AAT TCG GTT CTC CAA TCC
CCT GGG TCA CTT TGC TCT TGT GCA
CGC TTT CCA GTC TTT CAG CGT AAG
CCA GAG TCA TTC CCA AGG ATG CTG
GTT TCT CTC TGG GGG AAG AGC TGC
TCT GTG ATG GAG CCC ATG CGT GTC
ATC TGA GCC TCT GGC TTC CCT GCC
AGT GCA GCC CTG GCA GTG TCC TAC
TTC CCA GGG CTG TTG TCT GCC TGG
CGG GAA GGT CCT GGG CAA AGG ATC
AGT CTT

TGTACTCTGA GAGCAGACTA
CTTGGCTCCT CTCTGTTTTT
TATCAGCGAA

GTTGGATATA TCTCTCCAC
ATTTCCCTAA TCATATGCTA
TATATTGGCT

TTTTTTTTCT TCTCTAG

SEQ.I.D.NO:35

GTG AGG GCA GTC TTG CTT GAA TAG CTA ATG ATT CTT GAA

34

AAA TAG TAA GTG CCA GGG GAA ACC AAA TAC TGG ATT CTT
GAG CCT TTT TAT GCA TCT GCT TCA GTT TTA GGT GTG GCT AGG
GAA GGG AGC AGG CCT CAG GAA GGA ACC AGC ACT CTA AGA
CTG GCC TTT TTT TCC ACT AG

SEQ.I.D.NO:36

GTG GGG CCC AGT GCA GGA GGC GGG CCT GGT AGT GAG TTG
TTG GGT ATA GCC CCT GAC TGA TTT TTG TCC CCC AAC CTC CAG

SEQ.I.D.NO:37

GTG AGT AGA GGG AAC TGA TAG CAA AGG CAG AAG GGA GGA
TCC AAG GTG ATT CCC TCT CCA AGG GGA CAT CAG TGC CTC TCA
GGA AAG TAG C

AGCTTGGAAT AGAATCTGGC ATGCCTAAGG CCTTTGGGGA
ACTGGGATGC

TTATTTCTC TGCCTTCCTT GGCTGCCAC ATGGATGCCT
AAGTGTCTTC

CCTCCGGGAT AGAGTGTCT CCGTGACAT GCTGAAGAGT
TGTCTTTCTT

GACGTAG

SEQ.I.D.NO:38

CTA CGA TAT CGC TGT TGA TTT CCT TCA TCC CCT GGC
ACA CGT CCA GGC AGT GTC GAA TCC ATC TCT GCT ACA
GGG GAA AAA CAA ATA ACA TTT GAG TCC AGT GGA GAC
CGG GAG CAG AAG TAA AGG GAA GTG ATA ACC CCC AGA
GCC CGG AAG CCT CTG GAG GCT GAG ACC TCG CCC CCC
TTG CGT GAT AGG GCC TAC GGA GCC ACA TGA CCA AGG
CAC TGT CGC CTC CGC ACG TGT GAG AGT GCA GGG CCC
CAA GAT GGC TGC CAG GCC TCG AGG CCT GAC TCT TCT
ATG TCA CTT CCG TAC CGG CGA GAA AGG CGG GCC CTC
CAG CCA ATG AGG CTG CGG GGC GGG CCT TCA CCT TGA
TAG GCA CTC GAG TTA TCC AAT GGT GCC TGC GGG CCG
ATG TCT GCG AGC CAG GAT TCC CG

Claims

1. A DNA construct comprising a transcriptional regulatory sequence operatively linked to a heterologous gene of interest which sequence comprises a polynucleotide derivable from the eIF4A1 gene promoter or fragment thereof.
2. A DNA construct comprising a transcriptional regulatory sequence operatively linked to a gene of interest which regulatory sequence comprises a polynucleotide derivable from the eIF4A1 gene promoter or fragment thereof and at least one sequence derivable from a eIF4A1 gene intron.
3. A DNA construct comprising a transcriptional regulatory sequence operatively linked to a gene of interest which regulatory sequence comprises a polynucleotide derivable from the eIF4A1 gene promoter or fragment thereof and at least one intron sequence of the eIF4A1 gene wherein the intron sequence is selected from the group consisting of; intron 1, 2,3,5,6,7,9.
4. A construct according to any preceding claim wherein the eIF4A1 gene is mammalian.
5. A construct according to claim 2 or 3 wherein the intron sequence of the eIF4A1 gene is mammalian.
6. A construct according to any one of claims 2 to 5 wherein the intron sequence is intron 1.
7. A construct according to any one of claims 2 to 6 wherein the transcriptional regulatory sequence comprises a polynucleotide derivable from a plurality of eIF4A1 intron sequences.
8. A construct according to any preceding claim wherein the eIF4A1 gene promoter fragment is selected from the group consisting of; -526EIF, -371EIF, -271EIF, -193EIF, -120EIF, -98EIF, -69EIF and -40EIF.
9. A construct according to any preceding claim wherein the transcriptional regulatory sequence comprises a polynucleotide derivable from a variant of the eIF4A1 gene promoter which variant results from an addition, insertion, substitution, deletion,

rearrangement or modification of one or more bases of the eIF4A1 gene promoter.

10. A construct according to any preceding claim wherein the construct is a phage, plasmid, viral, minichromosome or transposon, preferably plasmid.
11. A construct according to any one of claims 2 to 10 wherein the eIF4A intron gene sequence is located downstream (in terms of reading frame) from the eIF4A gene promoter.
12. A construct according to any preceding claim further comprising one or more of the following; a terminator sequence, a bacterial origin of replication, a selectable marker.
13. A construct according to any preceding claim wherein the gene of interest encodes a therapeutically useful protein such as interferon- β , factor VIII, erythropoietin, growth factor or cytokine.
14. Host cell comprising (harbouring) a construct according to any preceding claim.
15. A host cell according to claim 14 wherein the cell is eukaryotic, preferably mammalian.
16. A process for the production of a protein which comprises the step of culturing a host cell according to claim 14 or 15 and optionally recovering the protein.
17. A method of treating a disease or disorder characterised by clinically significant cell loss (particularly neuronal cell loss) comprising the step of administering a therapeutically effective amount of the host cell according to claims 14 or 15.
18. A method according to claim 17 wherein the disease or disorder is Parkinsons.
19. A method of correcting or compensating for a disease or disorder whose etiology is characterised by a genetic aberration such as cystic fibrosis which method comprises the step of administering to a mammalian patient a therapeutically effective amount of the construct of any one of claims 1 to 13.
20. A medicament, particularly a pharmaceutical composition, comprising a construct according to any one of claims 1 to 13.

21. A medicament according to claim 20 wherein the construct is incorporated into a carrier such as a (cationic) liposome.
22. A method of treating a disease or disorder comprising the step of administering a therapeutically effective amount of the medicament according to claim 20 or 21.
23. A DNA construct comprising a transcriptional regulatory sequence operatively linked to a heterologous gene of interest which regulatory sequence comprises a polynucleotide having a sequence as set forth in SEQ.I.D.NO:38 or variant thereof.
24. A DNA construct according to claim 23 wherein the regulatory sequence further comprises one or more of the sequences as set forth in SEQ.I.D. NO: 31 to 37.
25. An isolated polynucleotide having a sequence as set forth in SEQ.I.D.NO:31 or variant thereof.
26. An isolated polynucleotide having a sequence as set forth in SEQ.I.D.NO:32 or variant thereof.
27. An isolated polynucleotide having a sequence as set forth in SEQ.I.D.NO:33 or variant thereof.
28. An isolated polynucleotide having a sequence as set forth in SEQ.I.D.NO:34 or variant thereof
29. An isolated polynucleotide having a sequence as set forth in SEQ.I.D.NO:35 or variant thereof.
30. An isolated polynucleotide having a sequence as set forth in SEQ.I.D.NO:36 or variant thereof
31. An isolated polynucleotide having a sequence as set forth in SEQ.I.D.NO:37 or variant thereof.
32. An isolated polynucleotide having a sequence as set forth in fig.9 at positions -2102 and -1082 or variant thereof.
33. An isolated polynucleotide having a sequence as set forth in fig. 9 at positions -1107 to -505 or variant thereof.
34. A construct according to any one of claims 1 to 13 for use in therapy.
35. A construct according to claim 34 for administration by particle mediated DNA delivery.
36. Use of a construct as claimed in any one of claims 1 to 13 as a vaccine.


39

37. Use according to claim 36 wherein the construct is administered by particle mediated DNA delivery.

Abstract

5 The present invention provides novel DNA constructs comprising a transcriptional regulatory sequence comprising a polynucleotide derivable from the eIF4A1 gene promoter. In preferred embodiments, the polynucleotide further comprises a polynucleotide derivable from the eIF4A gene introns, particularly intron 1. Host cells harbouring the constructs are also provided. These novel constructs have applications in gene therapy, DNA vaccines and in the commercial production of proteins.

Fig.1





|

-526

CTACGATATCGCTGTTGATTTCTTCATCCCCTGGCACACGT
CCAGGCAGTGTCTGAATCC

-466

ATCTCTGCTACAGGGGAAAAACAAATAACATTTGAGTCCAGT
GGAGACCGGGAGCAGAAG

-406

TAAAGGGAAGTGATAACCCCCAGAGCCCGGAAGCCTCTGG
AGGCTGAGACCTCGCCCCC

c-ets1

Sp1

-346

TTGCGTGATAGGGCCTACGGAGCCACATGACCAAGGCACT
GTCGCCTCCGCACGTGTGAG

-286

AGTGCAGGGCCCCAAGATGGCTGCCAGGCCTCGAGGCCTG
ACTCTTCTATGTCACTTCCG

c-

ets/Elk-1

-226

TACCGGCGAGAAAGGCGGGCCCTCCAGCCAATGAGGCTGC
GGGGCGGGCCTTCACCTTGA

Sp1

-166

TAGGCACTCGAGTTATCCAATGGTGCCTGCGGGCCGGAGC
GACTAGGAACTAACGTCATG



3/17

AP-2

CRE-BP

-106

CCGAGTTGCTGAGCGCCGGCAGGCGGGGCCGGGGCGGCC
AAACCAATGCGATGGCCGGGG

AP-2 Sp1 Sp1

Sp1

-46


CGGAGTCGGGCGCTCTATAAGTTGTCGATGGGCGGGCACT
CCGCCCTAGTTTCTAAGGAT


+14 C ATG TCT GCG AGC CAG GAT TCC CG

met ser ala ser gln asp ser





4/17

Fig.3




5/17
Fig.4





6/17


Fig.5






7/17

Fig.6






8/17

Fig. 7



9/17

Fig.8





1

10/17

Fig.9

-5280 GCGGCCGCAT AATACGACTC ACTATAGGGA TCTAGGAAGG CCTCTCATAG
-5230 CTGAGACGTG AATGATGAGC AGCCAGCCAT GCGCAGACCT GGAATAGCA
-5180 AGTACACAAG ACCCATAGTG AAAAACCATG GCTGAGGAAC AGAGGGCTTG
-5130 TGGGGGTGAC CTGTGTAGTT GGCGCAGAGT GAGCAAAGGG AGATGGATAC
-5080 AAAATTTCGGT CAGAGAGTAG ATCATGTAAG ACATGTACGG TAGGCTGAGG
-5030 AGGGGGGATT TTATTGCGTG TATACTGAGA AGCCATTGAG TTTAAGCAG
-4980 GCTGAGAAGT GCCTTCTGTT TTAAACTCCT GTTCAATGA CAGATTGAAA
-4930 GGGGGGCAAG AATGGAAGCA GGAACAGAGC ACAGTAGTCC AGGTGAGAAA
-4880 CTTGAACTGG AGTGCTAAAG GAAGAGAGAG AGAGTAGTTT TATGTAGGAT
-4830 AAATTTTACG AGTAAACCA GTAGGACTGA CAGGCTCTGT GATACTGAGA
-4780 GATACATATT TGTCTCCTGA CCAGGCTCCT GGCATTCAAC TTCTAAAATC
-4730 CTTGGAATCT CCAGTGATGT GTGTTTTTGT GTGCTGATGA GTTGATTCAT
-4680 GGCTAGCCCC TCTAGGTGGC TTCATGATTA GAGGGTTGGA ACTTTCAGCC
-4630 TCACCCCCAC CAACTTCCTG GGAGGGGAAT GGGGCCAAAG GTTAAGGCAA
-4580 TCAGTGAGGA TCAGTGATTT AATCAGTCAT GCCTAGTAGT GAAGCCTCTA
-4530 AAAACCGGAA AGGGGCCGGG TTGCGCGGCG CACGCCTGTA CTCCCGGCAC
-4480 TTTGGGAGGC TGAGGCAGAT GGATCGCAAG GTCAAGAGAT TGAGACCAGC

Alu I repeat

-4430 CTGGCCGACC TGGCGAAACC CTGTCTCTAC TAAAAATATG AAAATTAGCT
-4380 GGGCGTGGTG CGTGCGCCTG TAGTCCCCGG GAGGCTGAGG CAGGAGAATC
-4330 GCTTGAACCC GGGAGGCAGA GGTGTCAGTG AGCCGAGATT GTGCCACTGC
-4280 ACTCCACCCT GGGTGACAGA GTGAACTCT GTCTCAAAAA AGAAAAAAAAA
-4230 ACCCGAGAGG AGGAGTTTGG AGACATTCTA GATAGCTGAA GGCATGGAGG
-4180 CTGCCACAG GATGGTCTGC CAGGCCTCTT CCCGGTACCT TTCCCTGTGC
-4130 ATCTTTTCAT CTGTACTCTT TGTACTACCC TTTGTTAATA AACTGGTAAA
-4080 TGTGTTTCCA TGAGTTCTGT GAGCTGCTCT AACAAATTAA TCAAATTCAA
-4030 GGAGGGGGTC ATGGGAACGC TGATCTAACC AGTTGGTGAG AAACACAGAT
-3980 AAAACAACCT GGGGCTTACG ACTGGCATCA GAATTGGGGG CAGCCTTGTG



11

11/17

-3930 AGACTGAGCC CTAAACCTGT GACACATTAT CTCCAGGTAG ATAGTGTGG
-3880 AATTGAATTG GGGGATACCC AGCTGTGTCC ACCGCAAAAT TGCTTGCTTG
-3830 GTTGTGGTG GAGAGAAAGC CCCACAAACA CTTCTTGGTG ACCACAGGTT
-3780 ACAGAAGTAT TTTGTGTTGT GAGAGTATAG TAGGAAAGAA GATTTGTTTT
-3730 TTTGCCGGGC GCGGTGGCTC ACGCCTGTAA TCCCAGCCCT TTGGGAGGCT
-3680 GAGGCGGGCG GATCACCAGG TCAGGAGATC AAGACCATCC TGGCTAACAC
-3630 AGTGAAACCC TGTCTCTACT AAAAATACAA AAAATTAGCC GGGCGAGGTG

Alu I repeat

-3580 GCACGTGTCT GTAGTCCAAG CTACTTGGGA GGCTGAGGCA GGAGAATGGC
-3530 ATGAACCCAG GAGGTGGAGC TTGCAGTGAG GCAAGATCAC GCCACTGCAC
-3480 TCCAGTCTGG GCAACAGAGC AAGACTCCGT CTCAAAAAA AAAAAAAAAA
-3430 AAAAGATTG TTTTTCTC TGCAGGTTGG ATGTGGGAA TGAAGAAAA
-3380 GAAATGGAGG ATGATGCCTA GGTTTTTGGC CTATGTAACG GGAAAAGTGG
-3330 GAGAGGAACA GGTTGGGGGA GGAAAATGAA GAGTCTTTT CTCTTCTGGT
-3280 TTCCCTGCCC TCCCATTCAA AAGCCAGGAA ATTTCTACAG CTAGGCAGGA
-3230 TGATTGGCTC CGGCATTCTT TAATTTCACT CCTCAAAATC AAGAGCTTAC
-3180 ACCCTCAGGG ATCTTCTTGC AGTAGAGGGA AGGGTGGTGA CGTACAGTGA
-3130 AAAACATGTT GGCCTTCTTC AACTGAGTT TGAGTCCAC TTCTGCCATT
-3080 TCTTTCTTTC ATGACCTTGT GCAAGTCACG ACTTTCCAAG CTGCAATTTT
-3030 CTCATCTGTT AGGTTGAATG TTGAGAACTT CCCGGTAGGA TTGTTATGAG
-2980 CATTAAGTGC GTGTTTACTT TGTGCTGTGT CTTGTTCTAA GTGTATTATG
-2930 GATAGTCACT AGTTTAATCC TCATATCAAA TGGATGAGGT GTAGGTACTA
-2880 CTATTTACAC TCTCTGACAG ATAAGGAAAC TGAGGTATAG AAGGTTATTA
-2830 AGTAGGTTGC CCACTGTCAT AAGCCAGTAA ATGGAGGAGC TGTATTTGAA
-2780 TTCTGGCAGG CTCCAGAATC CTGGGCCTGG GTTCTTAGCT GCTAAGTGCT
-2730 TCTCCCTTTA AAGTGTGAAA AGCGCCTGCC CATCATGGGT TCTCAAGTGT
-2680 TCGTTCTGAT GTCTCCTCCA TTGTCTGACC TTCCTCCCTT ACCCCGAAGA
-2630 ACCGAAACAT GCAGATCCTG AGCTTGCCCA CAATCTAGGC CTTGGGTCTT
-2580 CTGTTCTTTC ACTTGGTTCC CTTACCTGTG TCTCTGTTCC TCTCTAGAAC



1
2
3

12/17

-2530 CTTTCATGGCA AAAGGCAAGA CTTCTGTTTG TTGTACCTGA CCTGTGGCAC
-2480 TATCTCTTTA GGTGGACATC TTCAATAAGG AGCTACTGCT AATCCCCATC
-2430 CACCTGGAGG TGCATTGGTC CCTCATCTCT GTTGATGTGA GGCGACGCAC
-2380 CATCACCTAT TTTGACTCGC AGCGTACCCT AAACCGCCGC TGCCCTAAGG
-2330 TTTGAGGGGG TAGGAGAGAG ATGGGCAAAA TGTGGGGCGG TGCAGTGGCA
-2280 AGGCATTGCA GGAAGAAGGG TGGGCTTTGG GTCTTTGAGG GGCGACCTGG
-2230 GCATGGTGTC TGCCAGCACT GTACCCACCA TACTGTGTTC AATTGAGAAA
-2180 CTTAGGGCAT CACTTTCTTT TCCCCATCC ACATAGCATA TTGCCAAGTA
-2130 TCTACAGGCA GAGGCGGTAA AGAAAGACCG ACTGGATTTC CACCAGGGCT
-2080 GGAAAGGTTA CTTCAAAATG GTGAGTTTCC TGAGGGAGGG GTATAGGGTG
-2030 TTGGTGGGGA CAGTGGTAGA AGGCAGAAAT TGAAGTCCTA CCCCTGGGAG
-1980 TCTCCATGTG AAGGGCCTGC TTTCTTTCTC TTCTCTAGAA TGTGGCCAGG
-1930 CAGAATAATG ACAGTGA CTGCTTTT GTGTTGCAGG TAAGCAGATG
-1880 ATGGGGCCAC CTCCTCTAGC TCTGAAGTCA GTTGGGTAA AGGGTCGGGA
-1830 GGCTGTTATG CATCCCCCTCA TTTGGCTCAT AGTCAGTTGT GGAGCAGGAA
-1780 GTAATCTGTT TTAGAACACC AAAACACTGG CTTCACTGGT TCTCTTCTGG
-1730 ACTTCTCCAT CCCACATTGG GACTGGGTCT CTAGGTCTTT TGGCTCTGGC
-1680 CTTTCATAGAG CTCCTGCTA ACCTCCA ACT CAGTGTATTT TCTCCATCTA
-1630 AAACATTCTA TCAAGTAAGA AACTAGCTT TAGAGTCAGG CTGTTTTTGA
-1580 ACCCCAGGCT GTGGGACCCT GGCTCCCTTT GGGGATGTTT TCTGAAGGAT
-1530 GGAGACACAT CTCATATGAA ATGTGTAGCA CAGGTCCTGA CACGGGGGGT
-1480 TTCTCATGGC TTGCTTTGTT AACACCCAGT ACTGCAAGCA TCTGGCCCTG
-1430 TCTCAGCCAT TCAGCTTCAC CCAGCAGGAC ATGCCCAAAC TTCGTCGGCA
-1380 GATCTACAAG GAGCTGTGTC ACTGCAAACT CACTGTGTGA GCCTCGTACC
-1330 CCAGACCCCA AGCCCATAAA TGGGAAGGGA GACATGGGAG TCCCTTCCCA

Homology to mouse eIF4A gene sequence

-1280 AGAAACTCCA GTTCCTTTCC TCTCTGCTT CTTCCCACTC ACTTCCCTTT
-1230 GGTTTTTCAT ATTTAAATGT TTCAATTTCG TGTATTTTTT TTTCTTTGAG
-1180 AGAATACTTG TNTATTTCTG ATGTGCAGGG GATGGCTACA GAAAAGCCCC



13/17

-1130 TTTCTTCCTC TGTTCGAGG GGAGTGTCG CCTGTGGCCC TGGGTGGAGC
-1080 AGTCATCCTC CCCCTTCCCC GTGCAGGGAG CAGGAAWTCA GNGATGGGGG
-1030 GNGGGGGGCG GACAATAGGA TNACAGCCCG CCAGATATNC ATATATATAT
-980 ATATATATAT ATATATATAT ATATATATAT ATATATATAT ATATATATAT
-930 ATATATATAT ATATATAAAA ATGCCACGGT CCTGCTCTGG TCAATAAAGG
-880 ATCCTTTGTT GATACGTAAG TGGTGGTCTT CCTTAAGGGG CTTCAAATTA
-830 GTGGATATGC TTAGCTCAGA CCTTCCAGCC AGTNTCTTGA GACTAAAGGG
-780 TTCAGCTTTC CATCCCTGGC TCAGGCACTG CCAACACCTT GTCTTCACCC
-730 AAACAAATCC CCCAGATGGG AGCAGAGAGC AGGAAGGAGG GAAAGTAGAT
-680 AAGCCTCAAG AATAAGGGCA TCCGAGAGGG AAGCGTGGGG AACTGGACAC
-630 AAGGGACTGG GGAGGGGACC AACCAGGATT CATGATAGTA CCCCAGGCC
-580 CTTTACAGTT TTYTTCCATC CCTCCACCAT CCAGCCAGGG GAATCCTCCC
-530 ATCCCTACGA TATCGCTGTT GATTTCTTTC ATCCCCTGGC ACACGTCCAG
-480 GCAGTGTCGA ATCCATCTCT GCTACAGGGG AAAAACAAAT AACATTTGAG
-430 TCCAGTGGAG ACCGGGAGCA GAAGTAAAGG GAAGTGATAA CCCCAGAGC
-380 CCGGAAGCCT CTGGAGGCTG AGACCTCGCC CCCCTTGCCT GATAGGGCCT
-330 ACGGAGCCAC ATGACCAAGG CACTGTCGCC TCCGCACGTG TGAGAGTGCA
-280 GGGCCCCAAG ATGGCTGCCA GGCCTCGAGG CCTGACTCTT CTATGTCACT
-230 TCCGTACCGG CGAGAAAGGC GGGCCCTCCA GCCAATGAGG CTGCGGGGCG


Homology to mouse eIF4A gene sequence

-180 GGCCTTCACC TTGATAGGCA CTCGAGTTAT CCAATGGTGC CTGCGGGCCG
-130 GAGCGACTAG GAACTAACGT CATGCCGAGT TGCTGAGCGC CGGCAGGCGG
-80 GGCCGGGGCG GCCAAACCAA TGCATGGCC GGGGCGGAGT CGGGCGCTCT
-30 ATAAGTTGTC GATGGGCGGG CACTCCGCC TAGTTTCTAA GGATCATGTC
+20 TGCGAGCCAG GATTCCCG



14/17

Fig. 10






11
12
13

15/17

Fig. 11





11


16/17

Fig. 12

Figure 12

00.31.2ptx2

11






•
•
•

17/17

Fig. 13



PCF/GB 00/02569

23/m Hed 5-7-2000

Glaxo Wellcome PLC